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Epilepsy has been associated with an increased fracture risk by various studies in the 
literature. This is attributed to the decreased bone mineral density (BMD) linked to the 
anti-epileptic drugs (AEDs) that are used to control seizures. As increasing age is also 
associated with decreasing BMD, older adults with epilepsy are at particular risk for 
fracture. There is no consensus on managing this risk and many epilepsy care guidelines do 
not address the risk at all. This is understandable considering the lack of adequate research 
on counteractive measures in this specific population. Moreover, though a prevailing 
theory explains the observed decreased BMD to be a result of AEDs reducing active vitamin 
D levels, the efficacy of vitamin D supplementation as a protective measure does not have 
robust evidence nor is there an agreed upon treatment regimen. The proposed project will 
aim to fill the gaps in the research and establish groundwork for future research on 
prevention and treatment by: examining the existing literature on vitamin D 
supplementation for bone health in adults with epilepsy; investigating the prevalence of 
osteoprotective behaviours and their impact on fracture occurrence in older Canadian 
adults with and without epilepsy; and determining the prevalence of vitamin D 
supplementation in the older adult Canadian epileptic population.  
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1.1 Epilepsy and Epilepsy-related Injuries 
 
Epilepsy is one of the most common neurological diseases in the world, affecting 
approximately 50 million people globally: between 4 to 10 per 1000 people1. Each year, an 
estimated 2.4 million people are diagnosed with epilepsy; infants and the elderly are at 
particular risk1,2. Idiopathic epilepsy, that is epilepsy with no clear underlying cause, 
accounts for 60% of all diagnosed epilepsy, therefore a decline in the incidence rate is 
unlikely until both all etiologies and their respective preventive measures are established1. 
Although Canadian estimates are not available, the overall economic impact associated 
with epilepsy in Europe was calculated to be €15.5 billion in the year 20043. In the United 
States new cases of epilepsy are associated with $362 million in costs for the first year of 
treatment and nearly $2 billion annually for existing cases4; according to 2015 estimates, 
Canada’s population is approximately 10% of the United States’ population and so the 
estimated Canadian cost could be in the tens of millions of dollars, a considerable amount 
5,6.  
One contributor to the costs associated with epilepsy is injury resulting from falls 
caused by seizures. People living with epilepsy have a 2–6 times greater risk of fracture; 
hip fractures notably are 2–3 times higher in both men and women with epilepsy7. 
According to a meta-analysis of 3 case-control, 1 cross-sectional and 8 cohort studies, the 
relative risk of fracture in individuals with epilepsy is 2.2 times that of those without. Of 
importance is the fact that while 35% of the documented fractures were seizure related, 




the remainder were due to other factors, particularly a significant decrease in bone mineral 
density (BMD) in patients with epilepsy8. Low BMD scores correlate with more fragile 
bones and, therefore, to fractures upon impact after a fall. One way to reduce the risk of 
injury by seizure-related falls is to minimize the occurrence of seizures.  
Although surgery is a treatment option in patients with epilepsy, it is typically only 
recommended to patients who do not respond to pharmacotherapy9. Even then 
approximately one third of patients with refractory epilepsy would not be eligible 
candidates10 as other factors like age, type of seizures and comorbidities are also taken into 
consideration11. Currently, there is no cure for epilepsy, only treatment. Anti-epileptic 
drugs (AEDs) are fairly successful in fulfilling this purpose and are able to control seizures 
in up to 70% of patients2. Moreover, a review by Schmidt and Loscher found that two thirds 
of patients continued to use AEDs even after epileptic surgery12 and a cohort study of 615 
individuals post-epileptic surgery found that of 365 that were “seizure-free”, only 28% 
were no longer taking AEDs13. AEDs are integral to the treatment of epilepsy. 
Unfortunately, AEDs are associated with reductions of BMD.  
1.2 Anti-Epileptic Drugs and Bone Health 
 
It is estimated that 20–65% of patients using AEDs develop osteopenia7. Both 
osteopenia and osteoporosis are defined by decreased bone density in comparison to 
healthy controls. According to the World Health Organization (WHO), osteopenia is 
characterized by a BMD that is 1–2.5 standard deviations below that of a sex and race-
matched healthy 30 year old whereas osteoporosis is more severe with a BMD of 2.5 or 
more standard deviations lower14. Using Dual-energy X-ray absorptiometry (DXA) 




measurements, which measures total bone mineral content of most trabecular bone 
including spine and ribs and can accurately detect a 5% change, 38–60% of 143 patients 
aged 18–89 treated with AEDs in tertiary epilepsy clinics would be classified as having 
osteopenia or osteoporosis15–19.  
This observed decrease in BMD in patients with epilepsy can be attributed to a 
number of factors outside of AEDs, several of which are associated with 
institutionalization: poor diet, lack of exercise and lack of sun exposure. However, after 
controlling for confounding factors a decline in BMD associated with AED use still exists16. 
Within a meta-analysis of 94 cohort and 72 case control studies investigating 80 risk 
factors for fracture among adults, an analysis of 3 case-control and 2 prospective cohort 
studies  of participants taking AEDs indicated that among participants aged 35 years and 
older AED use was associated with an increased fracture risk of 2.64 relative to those not 
on AEDs20. Overall meta-analysis of all studies indicated that AED use was consistently high 
risk for fractures related to bone mass loss whether the data was analyzed by study design 
and quality, age and sex of participants, fracture site or other study characteristics20. 
Longer use of AEDs appears to correlate with increasing risk of fracture: 12 or more years 
on AEDs results in a 4.15 relative risk of fracture compared to the 1.09 relative risk for less 
than 2 years of use; each year was associated with a 9% increase in relative risk according 
to an 8 year case control study of 40,485 patients with epilepsy with a median age of 39.1 
years21. In a population-based pharmacoepidemiological case-controlled study of 124,655 
patients with an average age of 43.44 years who had sustained a fracture in the year 2000, 
when data was unadjusted all AED use was associated with an increased fracture risk22. 
After controlling for confounding variables, such as prior facture or comorbidity with other 




conditions, carbamazepine, oxcarbazepine, clonazepam, phenobarbital were still 
significantly associated with any fracture; fracture risk associated with use of the 
remaining AEDs was in the same range, however due to low statistical power (e.g. 22 cases 
on ethosuximide compared to 1,804 on carbamazepine) they were not considered 
statistically significant22. Moreover, fracture risk at any location was found to be 
significantly higher when the AEDs in question were enzyme-inducing 22. 
1.3 Bone Loss: Overview 
 
Bone remodeling is the ongoing process of bone formation and resorption. 
Osteoblasts are responsible for the formation of bone while osteoclasts are responsible for 
resorption23. There is a balance between these opposing activities that is carefully 
regulated by several factors, including, calcium, vitamin D and PTH. Bone loss occurs when 
there is an imbalance in this process resulting in more bone resorption than formation and 
thus net bone loss. 
Calcium accounts for 1–2% of body weight and 99% of it is mineralized in tissue, 
particularly bone and teeth where it provides rigidity and structure. Circulating blood 
holds some of the remaining 1% of total body calcium. The plasma concentration of calcium 
is under strict homeostasis. Hypocalcemia would lead to increased release of calcium from 
bones to regain balance, therefore resulting in bone loss24. Parathyroid hormone (PTH) is 
one of the controlling factors of calcium homeostasis. Continuously enhanced levels of PTH 
increase the release of calcium from bones and, again, result in bone loss25,26. 
Hypophosphatemiahinders formation of the sites where new bone is made post-puberty27. 




Low serum calcium and phosphate are also partly responsible for osteomalacia: softening 
of the bone that, too, is characterized by low BMD and that facilitates fracture after 
injury28,29. In a study of 1105 women aged 43–80 years in which 99% of participants were 
post-menopausal, increased bone turnover was associated with rapid bone loss; high bone 
turnover is also thought to be associated with increased fracture risk independent of 
BMD30. 
1.4 Bone Loss: Proposed AED Mechanisms 
 
The mechanism by which AED use leads to a decline in bone health is not 
straightforward (see Figure 1). AEDs are associated with several bone metabolism 
abnormalities including hypocalcemia, hyperparathyroidism, hypophosphatemia and 
increased bone turnover15.  
Figure 1. Mechanisms of anti-epileptic drugs (AEDs) acting on bone 
 
PTH = parathyroid hormone, heavier weight arrows represent prevalent AED induction pathway 
 




 Other identified mechanisms that vary by drug are direct action on bone and 
interference with vitamin K metabolism, which promotes calcium integration into bone25,31. 
Of particular concern is enhanced conversion of active vitamin D to an inactive metabolite 
caused by AEDs that induce hepatic cytochrome P450 enzymes: carbamazepine, 
oxcarbazepine, phenobarbital, phenytoin and topiramate25. A suggested mechanism is that 
the decrease in biologically active vitamin D results in decreased calcium absorption in the 
gut, leading to hypocalcemia and increased circulating parathyroid hormone which in turn 
promotes bone turnover (Figure 1). For this reason, vitamin D supplementation is 
decidedly appealing as a countermeasure or, perhaps, a preventative measure. However, 
this potential mechanism does not explain all observed phenomena, such as the decreased 
BMD found in patients taking valproate, an enzyme inhibitor rather than inducer15.  A 
cross-sectional study examining the effect of long term AED therapy, 4 enzyme-inducing 
AEDs and 6 non-enzyme-inducing AEDs, on bone density in 42 ambulatory adult patients 
with a mean age of 33 found that both enzyme-inducing and non-enzyme-inducing AEDs 
were associated with decreases in BMD. There was a propensity for enzyme-inducing AEDs 
to yield lower spine, total hip, femoral neck and total body BMDs, but these differences 
were not statistically significant18. 
Newer non-enzyme-inducing AEDs are available. However some have still been 
linked to a detrimental effect on bone, though not necessarily by the same pathway as 
enzyme-inducing AEDs. For example, levetiracetam32 and lamotrigine33 have been linked to 
decreased bone health in human studies and zonisamide34 in rats. Moreover, the choice of 
AED by prescriber is based upon efficacy and tolerability in patients and is often influenced 
by past experience, recommendation by colleagues and affordability for patient35. 




Monotherapy, treatment with one drug, is ideal, but polytherapy, treatment with multiple 
drugs, is necessary for refractory epilepsy. Polytherapy is associated with a higher risk of 
bone metabolism abnormalities than monotherapy18. Prescription data from 2004 to 2009 
in Norway of an average of 44,611 patients on at least one AED found that carbamazepine 
and lamotrigine were the most commonly used in those aged 20–59 while carbamazepine 
and phenobarbital, both enzyme-inducing, were most commonly used in those aged 60–
102, a subgroup that is already at increased risk for osteoporosis and fractures. It should be 
noted that 18% of the population studied were on polytherapy and that 61% of the 
polytherapy was a combination of a non-enzyme-inducer paired with an enzyme-inducing 
AED36. An Italian database encompassing 289 general practitioners in the Caserta region 
analyzed over the years 2005 to 2011 found that phenobarbital and valproic acid, both 
associated with decreased BMD, were the most commonly prescribed AEDs for new 
incidences of epilepsy37. According to an analysis of an anonymous demographic and 
medical database compiled from general practitioners and specialists throughout Germany, 
of 43,712 adult patients using AEDs from 2010–2012, the top 4 drugs in use were 
valproate, levetiracetam, carbamazepine and lamotrigine38. Manitoba data from 1998 to 
2013 found that among people with epilepsy, phenytoin, carbamazepine, valproic acid and 
lamotrigine were the top four AEDs in use; the top two are hepatic enzyme-inducing AEDs 
and the third is an enzyme-inhibitor39.  An American study using national Veteran Health 
Administration, pharmacy and Medicare data on 72,358 patients 66 years and older found 
that between the years 1998 and 2004, the majority (67%) of those with newly diagnosed 
epilepsy were treated with phenytoin, followed by gabapentin (11%), carbamazepine 
(8.5%) and valproic acid (5.6%)40. Though newer AEDs with better side effect profiles are 




in use, the older AEDs associated with metabolic bone disease via the hepatic enzyme-
induction pathway are still highly prescribed, particularly in the older population that is 
more vulnerable to osteoporosis and fracture. 
1.5 Bone Health: Osteoprotective Measures for the General Population 
 
Regardless of the exact underlying mechanisms, there is a considerable amount of 
evidence indicating a relationship between AED use and reduction in BMD which has the 
capacity to lead to bone disease and, ultimately, fractures. Thus, counteracting this effect by 
improving BMD is a clear cut approach to reducing AED associated fractures. Genetics are 
thought to moderate up to 80% of the peak bone mass of an individual. However 20% or 
more depend on lifestyle factors. Prospective interventional studies in youth have 
demonstrated the beneficial effects of both calcium intake and exercise on BMD41. As peak 
bone mass is achieved in early adulthood, the main determining factor for bone health in 
adults and the elderly is bone loss and the prevention thereof.  
Exercise has been found to continue to be of benefit to bones in older age. Cross-
sectional studies have calculated an 8% greater BMD in individuals under 50 years of age 
who participate in exercise programs as compared to matched controls and a 6% 
difference in those over 5042. Longitudinal studies derived more modest results: a 2% 
increase in BMD in adults under 50 associated with exercise and a 1% increase for those 
over 50 years old42.  
Calcium and vitamin D, a main proponent of normal calcium metabolism, also 
continue to be valuable to bone health in older age. A three year study in adults aged 65 




and older found that calcium and vitamin D supplementation moderately reduced bone 
loss in the femoral neck, spine and total body and also reduced the incidence of non-
vertebral fractures43. A meta-analysis of 29 randomized trials in people aged 50 and over 
had similar findings: depending on whether study outcomes were fracture risk or BMD 
based, calcium and vitamin D supplementation were associated with a 12% decrease in 
fracture risk or 0.54% reduction in the rate of bone loss at the hip and a 1.19% decrease at 
the spine as compared to those not taking supplements44. A Cochrane review of the 
literature up to December 2012 included 53 medical trials and 91,791 participants over 65 
years old that investigated fracture outcomes with vitamin D supplementation or vitamin D 
and calcium supplement combination treatment as compared to placebo control or calcium 
supplementation only control45. This review concluded that though there was high quality 
evidence for combined vitamin D and calcium supplementation reducing the risk of any 
type of fracture, there was also high quality evidence that vitamin D supplementation 
alone, in doses no higher than 800 IU, was unlikely to prevent fractures45. Beneficial 
findings of vitamin D supplementation appear to be at more robust doses; doses of 1800–
4000 IU have been suggested44–46.  
Exercise as well as calcium and vitamin D intake have shown to enhance bone health 
to some degree in normal adults in research. The application of this research to the general 
population requires both the advocacy of these osteoprotective behaviours by health care 
professionals as well as guidelines on recommended amounts of exercise and 
supplementation for health care professionals to follow. 
1.6 Bone Health: Recommendations for the General Adult Population 
 




Osteoporosis Canada cites Canada’s Physical Activity Guide, stating that all adults, 
including those over 65 years, should participate in 30 minutes or more of moderate to 
vigorous intensity physical activity for 5 days a week or more. Moderate activity is 
classified as activity during which one would not be able to sing. Vigorous activity is 
classified as activity during which one would be able to neither talk nor sing. Strength 
training, such as weight lifting, and balance training, such as dancing or Tai Chi, are 
suggested. Weight-bearing physical activity is emphasized: that is, activity in which bones 
and muscles of the legs and trunk work against gravity. Examples of weight-bearing 
physical activities are walking, jogging, step aerobics, dancing, stair climbing, soccer, 
basketball, volleyball and other sports that involve running or jumping. Cycling and 
swimming are not considered weight-bearing physical activity47. Physical activity is 
recommended by Osteoporosis Canada specifically to slow the rate of bone loss as well as 
to strengthen muscles to prevent falls. 
Health Canada recommends 600 IU or 15 µg of vitamin D per day for adults up to 70 
years of age and 800 IU or 20 µg for adults older than 7048. It is estimated that a young 
white person will obtain 1000 IU or 25 µg of vitamin D from 4 minutes ultraviolet B 
radiation on 25% of the body surface. Older individuals or people with darker skin can 
need up to 18 minutes of exposure for the same results: per day, this is enough exposure to 
accumulate over time to a significant amount of ultraviolet B radiation which can result in 
detrimental effects to skin49. Moreover, sun exposure can also be influenced by 
geographical location, season, and ambulatory status and so it is difficult to quantify an 
ideal exposure time or to guarantee adherence from non-ambulatory patients50. Canadians 
are considered to be at risk for vitamin D insufficiency or deficiency particularly during 




winter months, but possibly during the summer as well due to geographical location49. 
There are vitamin D-fortified products on the market; in Canada only cow’s milk and 
margarine are required to be fortified. The vitamin D content does not transfer well to 
dairy products made from fortified milk, such as yogurt and cheese48. Calcium is generally 
acquired through dietary intake: Health Canada recommends between 1000–1200 mg of 
calcium per day for adults depending on age and gender48.  
Diet can prove insufficient for acquiring all necessary nutrients and, as mentioned 
above, acquiring an optimal amount of vitamin D via sunlight can be difficult, particularly 
for Canadians. Supplementation therefore becomes a simple alternative to ensure a fixed 
intake of both vitamin D and calcium. However, in the case of calcium supplementation, 
adverse effects such as kidney stones, gastrointestinal issues and, potentially, increased 
cardiovascular mortality have been observed51. The American Society for Bone and Mineral 
Research states that calcium supplements should only be used when adequate calcium 
cannot be obtained through the diet52. Unfortunately, high dairy intake is less tolerable in 
older adults and for many of them supplementation becomes necessary51. 
1.7 Bone Health: Recommendations for Adults with Epilepsy 
 
Guidelines offered by the American Epilepsy Society do not mention bone health or 
treatments for AED associated bone loss except for a link to a paper on the treatment of 
new onset epilepsy by French et al. that notes vitamin D levels are affected by AED use53,54. 
A drug safety update in 2009 in the U.K. warned about the “adverse effect on bones” of 
AEDs. The drugs specified in this safety update were carbamazepine, phenytoin, primidone, 
phenobarbital and valproate. At risk patients were identified: “those who are immobilised 




for long periods, those who have inadequate sun exposure, those with inadequate dietary 
calcium intake.” Vitamin D supplementation was recommended only for those considered 
at risk; no dosage recommendations were made55.  
The International League Against Epilepsy offers the National Institute for Health and 
Care Excellence (NICE) epilepsy guideline which, as of a new addition in 2012, denotes that 
a high level of vigilance must be taken for adverse effects of AEDs, such as bone health 
issues. However, outside of this brief mention, the guideline has no specific 
recommendations56. Instead, it is stated that blood tests, such as those for bone 
metabolism, should be taken into consideration to determine any comorbidities or if there 
is just cause, but these blood tests are not recommended to be conducted regularly unless 
clinically indicated56.   
Bone health is not mentioned by Epilepsy Canada. However, the epilepsy 
management guideline of Critical Care Services Ontario recommends screening for 
osteopenia and osteoporosis for patients on AED therapy. Full blood count, electrolytes, 
liver enzymes, vitamin D levels, and other tests of bone metabolism are indicated every 2–5 
years for adults taking enzyme-inducing AEDs10. There are no treatment recommendations 
stated except for post-menopausal women, who are recommended to avoid enzyme-
inducing AEDs and take daily vitamin D and calcium supplements10.  
The Scottish Intercollegiate Guidelines Network (SIGN) epilepsy guideline also has a 
section specifically on bone health. It states that patients taking AEDs should receive 
dietary and other lifestyle advice to reduce the risk of osteoporosis. Bone health in post-
menopausal women with epilepsy is highlighted, though once again there are no specific 




treatment recommendations57. A randomized control trial attempting to implement the 
SIGN epilepsy guidelines was conducted in 2003, the year of its previous draft publication. 
Encompassing 38 general practices over 3,000 square miles, adherence to the guideline 
was poor58.  
An accepted treatment of bone health in patients with epilepsy taking AEDs has not 
been established. In fact, not all epilepsy guidelines acknowledge the risk of bone 
metabolism abnormalities caused by AEDs. Moreover, those guidelines that do caution 
against the negative effects of AEDs on the bone do not specify any recommendations to 
deal with this possibility, presumably leaving it to the individual clinician’s discretion. A 
common treatment would be supplementation of vitamin D or calcium or both, although 
there is no agreed upon standard dose. This is concerning, as evidence shows that the 
recommended doses of vitamin D are not high enough to be clinically relevant even in 
people without epilepsy44–46. As far back as 1998, the lack of guidelines for treating bone 
metabolism disease in epilepsy has been criticized, with suggestion for up to 2 times the 
typically prescribed doses of vitamin D supplementation59. This suggestion was in turn 
scrutinized for not going into greater detail, ignoring age, AED type and other factors60. A 
study in 2001 looking at the practice patterns of neurologists found that only 28% of 
neurologists treating adults with epilepsy evaluated their patients for bone disease and 
only 7% prescribe prophylactic calcium or vitamin D. Of those that find evidence of bone 
disease, 37% treat with calcium or vitamin D, 57% refer to a specialist and 7% take no 
action61. With insufficient guidelines, the majority of neurologists do not appear to monitor 
bone health in their adult patients with epilepsy. For those that do, there is an apparent 
variability in their professional response to a diagnosis of bone disease. 




There is insufficient literature with recommendations to treat or prevent reduced 
BMD in individuals with epilepsy. Of the existing literature, there is a particular focus on 
women, especially post-menopausal women.  This is to be expected: despite a similar rate 
of bone loss in men and women starting from the mid-30s, as women approach menopause 
they begin to lose bone at a rate of 2–3 percent higher per year than men 62. Women are 
also at greater risk for fracture than men at any age and at age 50 and above the disparity is 
such that the lifetime risk for hip, forearm or vertebral fractures in white women is 39.7% 
compared to 13.1% in white men63. Penovich et al. recommended DXA scans of the spine 
and hip in at-risk women be collected and repeated every 2 years or if a fracture occurs64. 
Dietary counselling and supplementation to meet daily needs divided into 2–3 doses per 
day for optimal absorption were also recommended 64. However, a case note review and 
patient questionnaire by Kampman et al. in 2005 demonstrated that despite local 
recommendations of 800 IU vitamin D and 1,500 mg calcium in women with epilepsy on 
carbamazepine, phenobarbital, phenytoin or primidone, less than 5% of women treated 
with enzyme-inducing AEDs were informed of this65. Kampman et al. concluded that 
awareness of the issue of bone health in patients on AEDs among neurologists and patients 
had not increased compared to a survey completed in 199565. Again, it is important note 
that the recommended vitamin D dose is much lower than doses that have proved to be 
clinically relevant and even these lower recommendations were not being followed. 
1.8 Bone Health: Current Osteoprotective Behaviours in Individuals with Epilepsy 
 
Although there is not much research in the area, one study investigating vitamin D 
and calcium supplementation in adults with epilepsy using the patient database at the 




Veteran Affairs Medical Center in Lexington, Kentucky found that between October 1998 
and March 2007, 4.9% of their sample, whose mean age was 55.7 years, had documented 
calcium and vitamin D supplement usage while taking AEDs66. Alternatively, another 
American survey completed by 260 adult patients from an epilepsy clinic, whose mean age 
was 41.9 years, found that 25.4% reported regular calcium and vitamin D supplement 
usage67. In comparison, between 2007 and 2009, 31% of Canadians aged 6 to 79 years old 
reported taking a vitamin D supplement and between 2005–200668, 37% of Americans 
aged 1 year or older reported taking a vitamin D supplement69. Considering the disparity in 
American findings, an accurate reflection of vitamin D use in Canadian adults with epilepsy 
is needed. Previous estimates do, however, indicate that vitamin D supplementation may 
be low in this especially vulnerable group. 
 A study investigating exercise, diet and other health behaviours in adults with 
epilepsy using data from the 2005 California Health Interview Survey concluded that the 
diet and exercise behaviours of Californian adults with epilepsy were comparable to the 
general population and under the levels recommended by experts70. This was confirmed by 
a study using 2005 Canadian Community Health Survey (CCHS) data that demonstrated no 
difference in physical activity between those with epilepsy and those without between the 
ages of 12 to 39 years71. This excluded adults at higher risk of developing osteoporosis. A 
second study using 2001 to 2005 CCHS data addressed physical activity in several chronic 
conditions. According to this study, individuals with epilepsy were 1.4 times more likely to 
be physically inactive than the general population; the population of interest included 
those 12 years and over and trends in age groups were not investigated72. A clinical study 
comparing 35 epilepsy patients to 36 controls found that physical fitness as measured by 




walking, knee-dips, pelvis elevations and flexibility was significantly lower in the epileptic 
group at every test.  Moreover, body mass index was significantly higher in the epileptic 
group73.  Importantly, all studies used data collected from 2005 and earlier. These studies 
also did not address potential differences in physical activity between age groups and did 
not place a particular emphasis on the older population which is at increased risk of 
osteoporosis. In fact, one of the stated studies excluded this subpopulation 
1.9 Summary 
 
Epilepsy is a common and costly condition to the health care system and those 
personally afflicted. Injuries, particularly fractures, are associated not only with seizures 
themselves but also the medications used to control seizures. This is of particular concern 
in adults: both the osteoporosis clinical practice guidelines and the National Osteoporosis 
Foundation cite individuals 50 years of age and over to be at increased risk for 
osteoporosis and fracture as compared to younger individuals74,75. As underlying 
mechanisms of the decline in BMD associated with AED use are not yet delineated, the best 
corrective and preventative therapy is to enhance bone health. Known strategies to 
improve bone health in the general adult population consist of physical exercise and 
adequate calcium and vitamin D. Unfortunately these strategies have not been well studied 
in adults with epilepsy despite abundant evidence of the relationship between decreased 
bone health and AEDs. A comprehensive evaluation of the effect of vitamin D 
supplementation in particular on bone in adults with epilepsy would not be remiss, in light 
of the vitamin’s hypothesized central role in the mechanism many AEDs are suggested to 
act through. 




A consensus on the management of metabolic bone diseases in patients with 
epilepsy has not been reached. Although there exists an Ontario guideline for epilepsy that 
acknowledges the issue and puts forth some recommendations for managing the potential 
for developing bone disease, particularly in post-menopausal women, these instructions 
are not thorough. Moreover, follow up studies conducted in other countries do not inspire 
confidence in the adherence to such guidelines. As such, it is crucial to determine the 
current dietary choices, physical activity, sun exposure and vitamin D supplement use in 
the adult Canadian epileptic population, a group that is vulnerable to bone loss from both 
increasing age as well as the medication necessary for seizure control. Knowledge of 
current osteoprotective behaviours in the epileptic population would be reflective of 
current epilepsy health care in Canada and could possibly support any future alterations in 
treatment guidelines. It could also be used to guide strategies to improve rates of these 
protective lifestyle behaviours, perhaps through increasing accuracy of sample size 
estimation for future research.  
  




2 The Research Purpose 
 
2.1 Research Questions 
 
The overall purpose of this project was to build a firm foundation regarding the issue of 
decreased bone health in individuals with epilepsy. Specifically this project aimed to 
determine the current state of osteoprotective measures in people with epilepsy. To 
accomplish this, there are three main research questions to address. 
1. What is the effect of vitamin D supplementation on bone health in adults with 
epilepsy? 
2. What is the current level of osteoprotective behaviours in the adult epileptic 
Canadian population and how does this compare to those without epilepsy? 
3. What is the current prevalence of vitamin D supplementation in Canadian adults 
over 50 years old with epilepsy?  




2.2 Research Projects 
 
To address the stated research questions, three projects are proposed. 
1. A systematic review on the effect of vitamin D supplementation on bone health in 
adults with epilepsy 
2. A secondary data analysis investigating the calcium and vitamin D intake, physical 
activity and sun exposure as well as number of fractures in the adult Canadian 
population 
3. A survey on vitamin D supplementation as well as other inquiries regarding 
behaviours that impact bone health, epilepsy medication use and awareness of the 
potential negative effect of AEDs on bone health. 
  








As mentioned above, there is no consensus on the use of vitamin D supplementation 
specifically in people with epilepsy or the doses that would be recommended in this 
population. Recommended doses for the general population vary from 600–800 IU 
depending on age48. Systematic reviews have found that these doses are too low to be 
clinically relevant44,45. Considering the pathway that links enzyme-inducing AEDs to 
decreased bone health implicates reduced vitamin D levels25, efficacy and treatment 
regimen of vitamin supplementation may differ in people with epilepsy. Thus, the effect of 
vitamin D treatment on bone health warrants an investigation in people with epilepsy. 
3.2 Objective 
 
To investigate the effect of vitamin D treatment on bone health in adults with epilepsy 
in the existing literature as measured by outcomes such as bone turnover markers, bone 
mineralization and fracture occurrence. 
3.3 Methodology 
 
This systematic review was conducted following the PRISMA (Preferred Reporting 
Items for Systematic reviews and Meta-Analyses) guidelines76. Prior to commencement of 
the literature search, Prospero, the Cochrane Library and the Joanna Briggs Institute 
Library of Systematic Reviews were searched for any reviews on the topic of epilepsy77–79. 
No similar systematic reviews were found. 






Medline, PubMed, Scopus, Embase databases for articles from 1946 to 2015. Health 
Canada’s Clinical Trial Database, Cochrane Clinical Trials, Clinical Trials.gov, EU Clinical 
Trials, International Pharmaceutical Abstracts and Google were also searched to reduce 
publication bias. The grey literature procedure of Godin et al. was followed when searching 
Google80. The references of all full articles retrieved after passing the first stage of 
screening were reviewed as well. See Appendices A and B for a complete list of keywords 
and search terms.  
3.3.2  Study Selection: 
 
Studies were eligible for inclusion if they met the following criteria: studies on adult 
(≥18 years old) patients with epilepsy using at least one AED, a vitamin D supplement 
intervention and some form of bone health outcome measure (e.g. multiple bone turnover 
markers or bone mineralization). We excluded studies on children because of the rapid 
change in bone associated with growth before maturity has been reached. Studies had to 
demonstrate that a measured change is attributable to a vitamin D intervention. If a 
combination intervention of calcium and vitamin D was used a calcium-only control arm in 
the study was required for it to be eligible for inclusion. Only completed studies with 
original data were eligible: publications summarizing previously published studies were 
excluded and for eligible studies with overlapping patients the study with a larger sample 
size was kept. 




Studies were excluded if the extent of their outcome measures were to evaluate 
serum vitamin D levels and/or serum calcium levels alone with no bone outcome measure. 
Reviews, letters and case studies were also excluded. Studies that were not published in 
English were excluded. 
All studies were screened by at least two members of the research team (HF plus 
either CDH or MF; see Acknowledgement). Discrepancies were discussed by all three 
reviewers until agreement was reached.  
3.3.3 Data Extraction: 
 
The following data were extracted from eligible studies: authors, publication year, 
study location, study methodology, sample details (number of participants, sex, age, years 
of AED use), intervention details (dosing regimen, study length) and outcome 
measurements (bone turnover markers, bone mineralization). 
3.3.4 Quality Assessment: 
 
The methodological quality of included studies was independently assessed by two 
reviewers (HF & HM; see Acknowledgements) using a modification of the Newcastle-
Ottawa Scale for nonrandomized studies81,82 and the Cochrane Collaboration Tool Risk of 
bias assessment for randomized studies83. The modified Newcastle-Ottawa Scale includes 
items on statistical methods, confounding effects and reporting of data to assess 
methodological bias and excludes items on cohort follow-up, which are not relevant to 




studies included in this review; it also uses a more sensitive 4-point scale of assessment (0–
3 points per category) rather than the all or nothing scoring system of the original. 
3.4 Results  
 
3.4.1 Search Results 
 
Searches returned 769 articles; after removing duplicates 611 remained. Fifty-six 
articles were retrieved for full-text review after the initial screen based on title and 
abstract (kappa coefficient of 0.905, standard error of 0.031); of these studies nine met all 
eligibility criteria (kappa coefficient of 0.827, standard error of 0.096) (see Figure 2 and 
Appendix C). 
  




Figure 2. PRISMA Flow Diagram 
 
3.4.2 Studies Selected 
 
Four randomized trials and five non-randomized, quasi-experimental studies were 
eligible for this review84–92. Ages of participants ranged from 18 years to 92 years. All 
studies included both males and females; proportion of female patients ranged from 17%–
73%. Sample size ranged from 6 to 226. Study length ranged from 1 month to 12 months. 
Several AEDs were used by patients in the studies: phenobarbital, phenytoin, primidone, 
Excluded (n = 47) 
Does not meet bone outcome measurement criteria (n = 14)  
Vitamin D for seizure control (n = 4) 
Vitamin D via sunlight (n = 2) 
Case studies (n = 4) 
Children only/Data for adults and children not separated (n = 3) 
Don’t differentiate between calcium and vitamin D (n = 7) 
Non–unique data (n = 3) 
Non–English (n = 3) 
Full article unavailable (n = 7) 
Duplicates (n = 158) 
Studies screened for eligibility (n = 611) 
Studies identified from database search (n = 769) 
Full articles screened (n = 56) 
Excluded (n = 555) 
Study question not specific to this review’s objective (n = 329) 
Reviews/Letters/No vitamin D effect measured (n = 181) 
Limited to children or animals (n = 45) 
Articles included (n = 9) 




carbamazepine, valproate, topiramate, lamotrigine, gabapentin, clonazepam (see Appendix 
C). Only one of the nine studies investigated patients who were taking non enzyme-
inducing AEDs88. One of the nine studies restricted its patients with epilepsy to those who 
had evidence of osteopenia and at least one documentation of hypocalcemia85,while two 
recruited patients with increased amount of osteoid or an increase in the osteocytic 
osteolysis86,89. Post-vitamin D intervention data in the study conducted by Offermann and 
colleagues is visually represented thus the authors’ own descriptions of results are used to 
compensate for lack of measurement values90. 
3.4.3 Bone Health Indicators 
 
Outcomes reported by different studies varied: five studies reported serum vitamin 
D (25-hydroxycholecalciferol, 25-OHD)85–87,90,91, eight studies reported serum calcium and 
alkaline phosphatase (ALP) levels84–87,89–92, four serum parathyroid hormone (PTH) 
levels84,85,89,90, four inorganic phosphate85,86,89,92 and six reported on bone mineralization 
84–86,88,89,91 (Appendix C). Of the seven studies that measured alkaline phosphatase, one of 
them stated explicitly that the bone-specific isoenzyme was measured87 while six measured 
total serum alkaline phosphatase.  
3.4.4 Quality Assessment 
 
The methodological quality of included studies indicated all were of at least 
adequate quality (each scoring 50% or higher on the scales used), with randomized 
controlled trials consistently scoring higher (Appendices D and E). The mean rating for 




randomized controlled trials was 4.5 out of a possible total of 6 using the Cochrane 
Collaboration tool93 while the non-randomized, quasi-experimental studies had a mean 
rating of 15.4 out of a possible 21 in the modified Newcastle-Ottawa Scale82. Descriptions of 
outcomes measured are provided in Appendix F. 
3.4.5 Baseline (pre-intervention) Findings 
 
Before examining changes in bone health after vitamin D administration, some 
studies compared the initial state of bone health indicators in people with epilepsy with 
that of those without epilepsy.  These measures included serum 25-OHD, serum calcium, 
serum ALP, serum PTH, serum phosphorus and bone mineralization.   
3.4.5.1 Serum 25-OHD 
 
Six studies investigated serum 25-OHD levels (Table 1)85–88,90,91. Of the three that 
made comparisons to controls, two found the mean serum 25-OHD levels of patients with 
epilepsy to be significantly lower85,91. Offermann and colleagues noted that 90.5% of 
patients with epilepsy had serum 25-OHD levels below 15 ng/mL, as opposed to 69.2% of 
controls90. Mikati and colleagues found that 34% of their patients with epilepsy had serum 
25-OHD levels below 10 ng/mL and 46% were between 10 to 20 ng/mL88, while Pedrera 
and colleagues found that 36% of their patients with epilepsy had serum 25-OHD levels 
below 15 ng/mL91. These patients would be considered either vitamin D deficient or 
insufficient88,90,91. 
3.4.5.2 Serum Calcium 
 




In the six studies that compared serum calcium in people with epilepsy to controls, 
all found that the mean levels were lower in patients with epilepsy, (Table 1)84,85,89–92. This 
difference was statistically significant in three studies85,89,91. In Offermann’s study this 
difference was not significant but it was noted that 71.6% of their epilepsy patients had 
subnormal serum calcium levels (below 2.25 mmol/L or 9.00 mg/dl) as compared with 
50.0% of controls90. Sherk & Snape did not state if the difference was significant; their 
groups with epilepsy had a mean serum calcium level at or below 9.00 mg/dl while the 
control groups had higher means (9.6 mg/dl and 9.9 mg/dl for males and females 
respectively)92. All other studies, whether differences between controls and patients were 
significant or not, had mean serum levels above 9.00 mg/dl. 
3.4.5.3 Serum ALP 
 
All six studies that compared ALP in patients and controls found that mean serum 
ALP levels were elevated in the patients with epilepsy (Table 1)84,85,89–92. Five studies found 
this difference to be statistically significant84,85,89–91; Sherk & Snape did not state if this 
difference was significant92. 
3.4.5.4 Serum PTH 
 
Four studies that investigated PTH reported that the mean serum PTH levels of 
patients with epilepsy was higher than that of controls85,89–91, a difference that was 
statistically significant in two studies (Table 1)85,91. Offermann and colleagues noted that 
83.2% of patients with epilepsy had serum PTH levels above 110 pg/mL as compared to 




79.2% of controls90 and Pedrera and colleagues found that 17% of the patients with 
epilepsy had serum PTH levels that were above upper accepted limits91. 
3.4.5.5 Serum Inorganic Phosphate/Phosphorous 
 
Of the three studies that investigated inorganic phosphate/phosphorous 85,89,92, two 
found that patients with epilepsy differed significantly from the control group (Table 
1)85,89, with one study finding that inorganic phosphate/phosphorous levels were 
significantly higher89 and the other significantly lower92. Sherk & Snape noted that the 
observed levels were considered clinically normal and did not stated any significant 
difference92. 
  












Serum 25-OHD (ng/mL) 
Hahn & Halstead, 1979 19.2±1.6 8.6±0.8 <0.001 62.6±9.3 <0.001 
Hoikka et al., 1982 — 5.2±1.5 — 33.4±14.8 <0.01 
Krishnamoorthy et al., 2010 — 24.36±3.42 — 31.53±3.27 <0.001 
Offermann et al., 1979 7.3 6.9 NS — NS 
Pedrera et al., 2000 31.2±8.6 22.0±12.1 <0.0001 88±25 <0.0001 
Serum calcium (mg/dL) 
Christiansen et al., 1973 9.90±0.35 9.56±0.33 <0.001 9.59 NS 
Hahn & Halstead, 1979 9.65±0.11 9.08±0.16 <0.01 9.49±0.18 <0.02 
Hoikka et al., 1982 — 9.38±0.48 — 9.50±0.52 NS 
Krishnamoorthy et al., 2010 — 9.24±0.31 — 9.93±0.26 <0.001 
Mosekilde et al., 1977 10.084±0.0
36 
9.932±0.068 <0.05 10.028±0.048 NS 
Offermann et al., 1979 8.96 8.68 NS — NS 
Pedrera et al., 2000 9.6±0.4 9.2±0.4 NS — NS 










Serum ALP (IU/L) 
Christiansen et al., 1973 5.1±1.4a 8.1±2.6a <0.001 7.8a NS 
Hahn & Halstead, 1979 65±5 138±23 <0.01 118±19 <0.02 
Hoikka et al., 1982 — 245±82 — 185±46 <0.05 
Krishnamoorthy et al., 2010 — 81.92±19.63c — 54.77±11.53c <0.001 
Mosekilde et al., 1977 147±4 198±11 <0.01 165±9 <0.01 
Offermann et al., 1979 30 42 <0.01 — NS 
Pedrera et al., 2000 94±36 185±52 <0.0001 118±35 <0.0001 










Serum PTH (pg/mL) 





<0.001 6.3±0.8 µL Eq/mL <0.05 
Mosekilde et al., 1977 67.5±2.2 61.8±7.1 NS 59.3±7.2 NS 
Offermann et al., 1979 203 243 NS — NS 
Pedrera et al., 2000 36.7±9.6 52.7±15.6 <0.0001 35.7±14.9 <0.0001 
Inorganic phosphate/phosphorous (mg/dL) 
Hahn & Halstead, 1979 3.82±0.13 3.27±0.18 <0.02 3.70±0.16 <0.02 
Hoikka et al., 1982 — 3.10±0.37 — 3.25±0.40 NS 
Mosekilde et al., 1977 3.65±0.06 3.90±0.12 <0.01 3.65±0.12 <0.05 








Values in table are given as mean90,92, mean±standard deviation84,86–88,91 or mean±standard error85,89; 
NS=not significant, a=King-Armstrong units, b=Bodansky units, c = bone-specific isoenzyme, F=female 
subjects, M=male subjects 
 




3.4.5.6 Bone Mineralization 
 
The five studies that investigated bone mineralization found that bone 
mineralization was lower in those with epilepsy compared to controls84,85,88,89,91. 
Bone Mineral Content 
Christiansen and colleagues found that the initial bone mineral content (BMC) of 
patients with epilepsy (87±16% of the calculated normal value) was significantly lower 
(p<0.001) than in those without epilepsy84. 
Bone Mass 
Hahn & Halstead found that in patients with epilepsy forearm bone mass was 
significantly lower (p<0.02) than in controls: 81.7±4.7 % of age-sex norm in epilepsy 
patients vs. 101.4±2.1% in controls85.  
 Bone Mineral Density 
Mikati and colleagues found that BMD was significantly lower (p<0.05) at all sites in 
patients with epilepsy both compared to their own age, sex and ethnicity-matched non-
epileptic controls and the manufacturer’s database age-matched control values88. T scores 
for lumbar spine (-0.87±1.06), total hip (-0.58±0.93), femoral neck (-0.70±0.97), trochanter 
(-0.5±0.94) and 1/3 radius (-0.85±1.05) were compared to zero; a score below zero 
denoted a mean BMD less than the mean from the manufacturer’s database88. 
 Ultrasound 




Pedrera and colleagues found that amplitude-dependent speed of sound 
measurements of non-dominant hands were significantly lower (p<0.0001) in patients 
with epilepsy (1926±104 m/s) than in controls (2036±74 m/s)91.  
 Biopsy 
Mosekilde and colleagues conducted quantitative morphometric analyses of 
biopsies in their patients with epilepsy, providing a more in-depth picture of bone health. 
Those with epilepsy initially had more uncalcified bone than controls as measured by 
relative osteoid volume (4.8±0.4% in patients vs. 2.1±0.3% in controls, p<0.01), osteoid 
surface (28.1±1.4% vs. 13.9±1.3%, p<0.01) and mean width of osteoid seams (12.2±0.4µm 
vs. 8.9±0.3µm, p<0.01)89. Patients with epilepsy also had increased bone resorption as 
measured by resorption surfaces (6.3±0.3% vs. 3.8±0.2%, p<0.01) and mean volume of 
periosteocytic lacunes (71.9±1.9µm2 vs. 52.0±0.7µm2, p<0.01) than did controls89. The 
percentage of trabecular bone surface active in bone mineralization was also significantly 
higher (24.7±1.2% vs. 13.5±1.3%, p<0.01) in patients than in controls89.  
3.4.6 Post-vitamin D Intervention 
 
3.4.6.1 Serum 25-OHD 
 
The five studies that measured changes in serum 25-OHD levels after vitamin D 
intervention noted an increase85–87,90,91, of which four were statistically significant (Table 
1)85–87,91. Offermann and colleagues noted a seasonal change in serum 25-OHD that 
appeared to be dose-dependent in individuals taking vitamin D supplements, such that 
higher dosed groups experienced larger, though not significant, increases90. 




3.4.6.2 Serum Calcium 
 
Six of the eight studies that measured changes in serum calcium levels after vitamin 
D intervention noted an increase84–87,89,92; three studies reported statistically significant 
findings (Table 1)85,87,92. Offermann and colleagues noted a seasonal change in serum 
calcium that appeared to be dose-dependent in individuals taking vitamin D supplements90. 
3.4.6.3 Serum ALP 
 
Seven of the eight studies that measured change in ALP found a decline in serum 
levels after vitamin D administration84–87,89,91,92, of which six were statistically significant 
(Table 1)85–87,89,91,92. 
3.4.6.4 Serum PTH 
 
Of the four studies that measured change in serum PTH, two found a significant 
decrease after vitamin D administration85,91 while two did not observe any change (Table 
1)89,90. Offermann and colleagues noted that vitamin D administration lowered the 
frequency of abnormal PTH levels in their patients90. 
3.4.6.5 Serum Inorganic Phosphate/Phosphorous 
 
In two of the four studies that measured serum inorganic phosphate/phosphorous a 
significant change was seen after treatment, an increase in one study85 and a decrease in 
the other (Table 1)89. 
3.4.6.6 Bone Mineralization 
 




Six studies investigated bone mineralization and all observed some positive changes 
after vitamin D treatment84–86,88,89,91, though of these one study found a change in bone 
morphology but not BMD86. 
Bone Mineral Content 
When comparing patients with epilepsy taking enzyme-inducing AEDs for at least 
one year who also took 350 mg/day of calcium combined with 2000 IU/day of vitamin D2 
to a control group without epilepsy on the same regimen, BMC had increased significantly 
(p<0.001) by 4.9% above baseline values, whereas there was no significant change in 
controls84. 
 Bone Mass 
At a dose of 4000 IU per day (2000 IU twice daily) of vitamin D3 for 4 months, a 
significant increase of 4.6% (p<0.02) in forearm bone mass from baseline was observed in 
patients taking enzyme-inducing AEDs for more than two years85. 
 Bone Mineral Density 
When measuring BMD with DXA, Mikati and colleagues found that after 12 months 
of either 400 IU or 4000 IU daily vitamin D2 administration BMD at all sites remained 
significantly lower than in controls as well as relative to the manufacturer’s database 
values88. BMD of patients in the low dose arm did not change significantly from baseline 
however patients in the high dose arm of the study had a significant increase in BMD at 
several sites: lumbar spine (p<0.03), total hip (p<0.02), and 1/3 radius (3 of 5 sites, 
p<0.04)88. Though significant, this increase was less than 1% from baseline. Patients in the 




low dose arm of the study were significantly older than those in high dose arm (p<0.01) 
and their duration of AED therapy was also significantly longer (p<0.04)88. These 
researchers conducted linear regression and stated that age and AED duration did not 
appear to influence the results in the two treatment arms88. Hoikka and colleagues 
measured BMD using the gamma ray attenuation method and found no statistically 
significant difference from baseline in patients with epilepsy after 6 months treatment with 
2000IU daily vitamin D286. 
Ultrasound 
Pedrera and colleagues found that ultrasound measurements of non-dominant 
hands increased significantly (p<0.0001) from baseline (1926±104 m/s to 2000.1±98 m/s) 
one month after a single administration of 120,000 IU of vitamin D391. 
 Biopsy 
After taking 9000 IU vitamin D2 daily for nine months, patients with epilepsy in 
Mosekilde’s study had a decrease in uncalcified bone from baseline measured by biopsy89. 
Specifically, relative osteoid volume (4.8±0.4% at baseline vs. 2.2±0.3% post-treatment, 
p<0.02), osteoid surface (28.1±1.4% vs. 21.8±1.6%, p<0.01) and mean width of osteoid 
seams (12.2±0.4µm vs. 8.9±0.7µm, p<0.01) decreased significantly from baseline and both 
relative osteoid volume and mean width of osteoid seams were no longer significantly 
higher than controls89. The percent of osteoid surfaces remained significantly higher than 
controls (p<0.01) even after vitamin D treatment89. Bone resorption as measured by 
resorption surfaces (6.3±0.3% vs. 4.8±0.4%) and mean volume of periosteocytic lacunes 
(71.9±1.9µm2 vs. 53.1±1.7µm2) also decreased significantly after treatment (both p<0.01); 




however, while the difference in the mean volume of periosteocytic lacunes between 
patients and controls were no longer significantly different, the resorption surfaces 
remained significantly elevated in patients with epilepsy than in controls (p<0.05)89. After 
vitamin D treatment, the percentage of trabecular bone surface active in bone 
mineralization was also significantly decreased in patients (24.7±1.2% vs. 13.0±0.9%, 
p<0.01) and was no longer significantly different from that of controls90. The biopsies of 
patients treated with 6 months of 2000 IU daily vitamin D2 showed a significant (p<0.02) 
decrease in relative osteoid volume (9.0±5.6% pre-treatment vs. 4.0±2.1% post-
treatment); Hoikka and colleagues noted that five of the sample of nine’ values returned to 
a normal range86. 
3.4.7 Bone Health Indicators in Patients with Epilepsy Treated with Calcium Alone vs. 
Calcium + Vitamin D 
 
Two studies used a calcium control of either 390 mg84 or 1000 mg87 daily in the 
patient groups such that one group with epilepsy received calcium only and another group 
with epilepsy received calcium as well as vitamin D supplementation84,87. 
3.4.7.1 Serum 25-OHD 
 
Serum levels of vitamin D decreased significantly in individuals with epilepsy 
treated with 1000 mg of calcium daily for 90 days (Table 2)87. Patients treated with 1000 
mg calcium and an additional 400 IU daily of 25-OHD for 90 days had a significant increase 
in vitamin D serum levels (Table 2)84. 




3.4.7.2 Serum Calcium 
 
Patients receiving 390 mg of calcium daily for three months with or without 2000 IU 
of vitamin D2 did not see a significant change in serum calcium levels post-treatment 
(Table 2)84. Patients receiving 1000 mg of calcium daily for 90 days had significant 
decrease in serum calcium levels while those receiving additional 25-OHD had a significant 
increase in serum calcium levels (Table 2)87. 
3.4.7.3 Serum ALP 
 
In Christiansen’s study, both groups did not see a significant change after treatment 
(Table 2)84. On the other hand, although Krishnamoorthy’s study reported a significant 
decrease in serum ALP levels in the 1000 mg calcium with 400IU vitamin D daily treatment 
arm, a significant increase was detected in the calcium-only treatment arm (Table 2)87. 
3.4.7.4 Bone Mineral Content 
 
Both epileptic treatment groups saw an increase in BMC from baseline, but this 
change was only significant in individuals treated with vitamin D supplement along with 
calcium (Table 2)84. 
 
  




Table 2. Comparison between calcium alone and calcium plus vitamin in patients with epilepsy. 




Our systematic review is the first to investigate the effect of vitamin D 
supplementation on bone health in adults with epilepsy who take AEDs. Bone health has 
been found to be compromised in people with epilepsy, particularly those taking enzyme-
inducing AEDs which decrease biologically active vitamin D levels. Increased fractures and 
decreased BMD have been found in this population15; this review addresses the impact of 
supplementing this decreased vitamin D in patients to manage this adverse effect. All 
outcomes assessed in this review (Appendix F) showed some change, typically an 




















et al., 2010 
25.19±5.98 19.76±5.35 <0.001 24.36±3.42 31.53±3.27 <0.001 
Serum calcium (mg/dl) 
Christiansen et 
al., 1973 
9.56±0.33 9.57 NS 9.56±0.33 9.59 NS 
Krishnamoorthy 
et al., 2010 




8.1±2.6a 8.1a NS 8.1±2.6a   
Krishnamoorthy 
et al., 2010 


















At baseline considerable proportion of adults with epilepsy were either vitamin D 
deficient or insufficient. Vitamin D deficiency has been classified as having a 25-OHD level 
of <10 ng/mL94; the World Health Organization classifies insufficiency as a 25-OHD level of 
<20 ng/mL95. However, more recent research has classified vitamin D deficiency as a 25-
OHD level of <20 ng/mL and insufficiency as <30 ng/mL94. In the studies reviewed, patients 
with epilepsy had lower serum levels of vitamin D, up to twofold, than did controls84,85,89–92. 
Three of five studies had patients in the vitamin D deficient category by either convention 
with levels <9 ng/mL at baseline85,86,90; the other two studies had patients with baseline 
vitamin D levels between 22–25 ng/mL87,91 which is insufficient according to newer 
research94 but is considerably higher. A possible explanation for this discrepancy is 
geographical location: the two studies with higher baseline vitamin D levels in patients 
took place in India87 and Spain91 as compared to the three studies taking place in 
Germany90, Finland86 and the USA85. The main source of vitamin D is sunlight which varies 
by geographical location and by time of year which may also be a possible reason for 
observed differences96. It is important to note that of the two studies with higher baseline 
vitamin D levels in patients, the one study that compared to controls without epilepsy 
found that patients had significantly lower levels91. 
Although some studies found patients with epilepsy to have significantly lower serum 
calcium at baseline as compared to controls, the majority of patients with epilepsy still had 
serum calcium levels that fell into the normal range (a range of 8.7–9.9mg/dL in the 
included studies as compared to the approximate 8.9–10.4 mg/dL normal range for 
adults97). This is not unusual. Vitamin D deficiency with normal serum calcium is typical98. 
The mechanisms of calcium homeostasis exist to maintain normal serum calcium; this 




normal serum calcium may come at the expense of other abnormalities such as elevated 
PTH or increased release of calcium from the bone (degradation).  
Vitamin D treatment increased serum 25-OHD and calcium levels, though not always 
significantly. This has also been found in other studies (that did not meet the eligibility 
criteria for this review) investigating vitamin D treatment purely to correct vitamin D 
levels in patients with epilepsy99,100. In two of four studies, serum levels of the bone 
turnover marker inorganic phosphate/phosphorous were found to be significantly 
different, either higher or lower, in patients as compared to controls pre-vitamin D 
treatment and were normalized by a statistically significant amount post-treatment; the 
normalization of this bone turnover marker post-treatment suggests that vitamin D was 
positively effecting bone health85,89. 
In the studies reviewed, people with epilepsy typically had elevated levels of ALP and 
PTH at baseline, both of which can accompany low serum vitamin D98. The normal range of 
ALP is wide and varies greatly depending on age and sex (around 37–222U/L to encompass 
the ranges for adults aged 18 years and older)101. Many of the included studies did find 
baseline ALP levels in patients that were likely higher than the normal range, however this 
is difficult to ascertain when not looking at the individual and the range appropriate for 
their age and sex. Post-vitamin D treatment, these elevated levels tended to decrease, 
particularly serum ALP, after vitamin D treatment. Several case reports of people with 
epilepsy on long-term AED therapy also noted elevated ALP levels102.  
Both ALP and PTH are considered bone turnover markers and their elevated levels 
can indicate abnormal bone formation101,103. However, PTH levels that do not fall within the 




normal range may occur for a number of reasons, thus this hormone’s usefulness in 
determining bone health is more limited than other measures. Evidence showed an 
association between elevated ALP levels and risk of deteriorating bone condition. A 
prospective study on 512 post-menopausal women found that elevated serum bone ALP at 
baseline was significantly associated with osteoporotic fractures104. A systematic review of 
134 reports to investigate using bone turnover markers to assess osteoporotic status found 
moderate correlations between high ALP levels and low BMD scores and that elevated ALP 
levels might indicate a need for osteoporosis screening105.  
In our review, patients with epilepsy generally had elevated ALP levels as compared 
to controls without epilepsy. That finding along with the reported association between 
elevated ALP and decreased bone health suggest that ALP levels could be used as an 
indicator that vitamin D supplementation is required. It may also be possible to determine 
the range at which ALP levels are a concern and treatment should be started. To our 
knowledge this avenue has not been explored and further investigation is recommended.  
It is important to note that ALP has a number of sources including bone and liver. 
Considering that AEDs are inducers of hepatic enzymes, elevated ALP may be an indicator 
of liver health rather than bone health. However, hepatotoxicity is a rare side effect of AED 
therapy and is often idiosyncratic and not dose-dependent, therefore, raised total serum 
ALP levels may not necessarily be indicative106. Of the six studies included in this review 
that investigated serum ALP, the one study that measured bone-specific ALP observed a 
reduction post-vitamin D treatment similar to other studies that measured total ALP87. 
Another study measured leucin arylamidase, a liver enzyme whose elevation indicates 




damage, and concluded from the normal levels that both the initially raised ALP observed 
only in patients taking AEDs as well as the non-significant decrease in ALP post-vitamin D 
treatment were a result of the bone isoenzyme90. Pedrera and colleagues measured alanine 
aminotransferase and gamma-glutamyl transferase, markers of liver health, in their study 
and found that unlike ALP there were no differences in either of these markers between 
controls and patients at baseline and that they did not change post-vitamin D treatment 
despite reduction in ALP91. Therefore, an elevated ALP without a coinciding rise in gamma-
glutamyl transferase indicates a bone-specific origin103.  Hahn and Halstead measured total 
ALP but concluded, based on their previous study that the reduction in ALP seen after 
vitamin D treatment was due to the bone isoenzyme85. We must consider that the ALP 
changes observed in these studies were noted post-vitamin D intervention, while AED use 
remained constant; likely these changes in ALP were of bone origin rather than liver.  
Regardless, if ALP measurements were used in clinical practice as an indication that 
vitamin D treatment is necessary, measurement of the bone-specific ALP would be more 
convincing evidence than total ALP.  
The effect of vitamin D treatment on bone mineralization was difficult to ascertain 
because different measures (i.e., BMD, BMC, hand ultrasounds and biopsies) were used to 
determine this bone health outcome. However, all six studies that investigated bone 
mineralization found some positive change in at least one measure used84,86,88,89,91,99. The 
studies varied from 1 to 12 months, so duration of supplementation may be a confounding 
factor. For example, of the two studies that investigated BMD, a six month intervention 
with vitamin D supplementation did not see a significant change86 while a 12 month 
intervention did88. On the other hand, that 6 month intervention did find significant 




improvements in bone morphology which may suggest that some bone mineralization 
measurements need a longer period of treatment to yield observable results86. 
Another potential confounder is dosing. Pedrera and colleagues used a single 120,000 
IU dose of vitamin D and observed significant improvements91. Mikati and colleagues 
administered lower doses of either 400 or 4000 IU daily and noted no changes in BMD in 
their low-dose treatment arm88, which is consistent with research that has found doses 
below 800 IU to be of little effect44–46. The high-dose arm in Mikati’s study was within a 
range suggested to be effective88.  
Mikati found a less than 1% increase in total hip BMD after 12 months of vitamin D 
treatment (p<0.02)88 which was comparable to the results seen in male patients with 
epilepsy treated for 12 months with the bone loss drug risedronate107. A clinical trial that 
investigated larger supplement dosing of 1,000–1,500 mg calcium and 500–750 IU vitamin 
D daily paired with placebo or 35 mg risedronate weekly in 27 male veterans with epilepsy 
found a small but significant decrease of <2% from baseline in total body BMD in the 
placebo arm after two years as compared to a non-significant increase of <0.085% in the 
risendronate arm107. In this study the difference in efficacy between supplementation alone 
or with pharmacotherapy was not significant107. It is important to note that participants 
with subnormal serum calcium and vitamin D were excluded from the study, which may 
have had implications on the usefulness of calcium or vitamin D supplementation 
treatment in improving BMD107. The study was excluded from this review due to an 
inability to differentiate the effect of vitamin D from the effect of calcium supplementation 
in the combined treatment107. Similarly, it is important to note that Mikati’s study is the 




only one in our review that included patients who were taking non-enzyme-inducing AEDs, 
though the authors noted that the majority were taking enzyme-inducing AEDs88. This may 
have influenced the results as the effect of vitamin D intervention may be different in 
patients taking non-enzyme inducing AEDs as compared to patients taking enzyme-
inducing AEDs which have been linked to decreased vitamin D. 
Although all patients with epilepsy in the reviewed studies were 18 years of age or 
older, participants’ age, the AED(s) taken and the treatment history varied considerably. 
Hahn & Halstead restricted their participants to patients with epilepsy who had evidence of 
osteopenia and at least one documentation of hypocalcemia, which may have played a role 
in the significant increase seen in forearm bone mass observed after vitamin D treatment, a 
bone health indicator not measured in the other reviewed studies85. Similarly both studies 
that used biopsies restricted their patient groups, which may have limited the 
reproducibility of their results in all patients with epilepsy86,89.  
Moreover, the heterogeneity of study methodologies make findings difficult to 
generalize. Different types of vitamin D supplementation — e.g., D2, D3, 25-OHD — 
introduced yet another possible confounder. We found no relationship between the type of 
vitamin D administered and its efficacy in treating bone health, nor can we draw 
conclusions on the optimal length of treatment with vitamin D. Christiansen et al.’s follow-
up study to their 1973 investigation used a similar protocol but compared 25-OHD and 
vitamin D3 treatment, rather than the original vitamin D2 treatment, in people with 
epilepsy using phenobarbital and phenytoin108. In this later study, Christiansen and 
colleagues did not find significant changes in BMD unlike in their first study. Although their 




more recent study did not have a calcium-only control arm with which to compare the 
effect of the vitamin D and calcium combination treatment, therefore excluding it from this 
review, the authors concluded that the lack of observable effect on bone health was 
attributable to the type of vitamin D treatment used108. Two subsequent randomized, 
double-blinded trials testing calcium paired with 4000 IU/day of vitamin D2 or D3 for 6 
months in patients with epilepsy found no difference in patients using carbamazepine109 
but found that only vitamin D2 treatment was effective in patients using phenobarbitone 
and primidone110. Whether this means that only some types of vitamin D treatments are 
effective in improving bone health in people with epilepsy taking AEDs or whether this has 
implications on which specific AEDs are responsive to vitamin D treatment is not known. 
Further studies are warranted. 
Taking calcium, vitamin D or both is frequently recommended to maintain bone 
health. A Cochrane systematic review of 53 trials with participants 65 years of age or older 
found stronger evidence for combined calcium and vitamin D treatment than for vitamin D 
alone with respect to fracture outcome45. On the other hand, a meta-analysis of 29 trials 
with participants 50 years of age or older found evidence for both calcium treatment alone 
or combined calcium and vitamin D treatment in fracture outcome44. Both reviews noted 
that doses of vitamin D above 800 IU are necessary for observable outcomes and the 
Cochrane review which found less favourable evidence for vitamin D treatment did not 
include any trials with doses over 800 IU44,45.  Although the low vitamin D doses perhaps 
concealed possible benefits of vitamin D treatment in these reviews, calcium appears to be 
the more effective supplement to maintain bone health in the general population. However, 




for patients with epilepsy vitamin D plays a significant role in the mechanism that links 
many AEDs to bone health.  
Seven of the nine studies in our review assessed vitamin D treatment without the 
addition of calcium and found that bone health generally appeared to improve85,86,88–92. The 
remaining two studies evaluated the efficacy of combined vitamin D and calcium 
supplements relative to that of calcium-only treatment84,87. Including vitamin D in 
treatment appeared to provide some benefit. One study found that calcium treatment alone 
significantly decreased serum calcium levels and increased already elevated ALP in 
patients whereas combination treatment significantly increased serum calcium levels and 
decreased serum ALP87. The second study found no significant change in BMC in the 
calcium-only arm but found significantly higher BMC after combined treatment84. Despite 
being conducted 37 years apart by different researchers using different protocols and 
vitamin D supplement types, both studies support the use of vitamin D supplementation in 
people with epilepsy. Although evidence on the value of vitamin D supplementation on 
preventing fractures among the general adult population is limited, it appears to improve 
bone health in epileptic patients taking AEDs. It is worth noting that one of these studies 
used a low dose of 400 IU vitamin D yet still found significant results87. It is possible that 
the addition of calcium supplementation may have played a role in this. The dose of vitamin 
D, with or without calcium, necessary to see improvements in bone health is not yet known 
though doses of 800 IU have been suggested when used in combination with calcium44 and 
doses of 1800–4000 IU have been suggested when used46. 




More standardized intervention studies (dosing, duration, outcomes) are needed to 
evaluate the effectiveness of vitamin D on bone health in adults with epilepsy. The 
methodological quality of the reviewed studies ranged from medium to low risk of bias. 
The major concern between studies was a lack of replication. The effect of vitamin D 
treatment on bone mineralization suffers the most from a lack of standardized protocol and 
it is, arguably, the most important outcome of bone health as it is a better measure than 
bone turnover markers such as ALP and PTH. Findings linking vitamin D with bone health 
improvement are not fully conclusive. Many concerns have not been addressed, including 
the type of vitamin D used, the dose and duration of intake. There is also a lack of research 
on vitamin D supplementation in people with epilepsy that investigates fracture outcomes. 
Vitamin D intervention studies for bone health in the general population44,45 as well as 
osteoporosis drug studies in the general population111,112 tend to focus on fracture 
outcomes. Fracture outcome may be of more clinical significance when considering efficacy 
of a treatment targeting bone health. 
Only nine studies met our eligibility criteria and they were methodologically 
heterogeneous and conducted over a span of four decades. Consequently, it is difficult to 
determine the efficacy of vitamin D supplements to improve bone health in patients with 
epilepsy. Our review found some evidence that vitamin D supplementation may be 
beneficial to bone health in patients with epilepsy. Therefore, long-term studies that 
include comparable dosing schedules of vitamin D (preferably >1800 IU daily), bone 
turnover markers, BMD measurement and fracture outcomes are recommended to clarify 
the clinical role vitamin D supplements play in bone health management in patients taking 
AEDs.  








BMD peaks in early adulthood and begins to decline with age. At a certain point this 
decline becomes clinically relevant due to its ability to predict fracture occurrence113,114. 
Many AEDs have been associated with a detrimental effect on bone, including decreased 
BMD and this reduction appears to worsen with increasing years of AED use8,21,22. Although 
BMD is one of the better predictors of fracture risk it is not the only one. Along with 
increasing age, particularly those aged 50 and older, women have also been found to have a 
higher risk of fracture than men62,63,74,75.  Among older adults with epilepsy, there is an 
accumulation of risk: AED use and age as well as being biologically female for 
approximately 50% of this population. There is also the risk of falling associated 
specifically with seizure occurrence which increases opportunity for injury and fracture 
occurrence, particularly when paired with compromised BMD.  
Considering that in Canada 1.2 billion dollars was spent on osteoporotic fractures in 
the 2007–2008 fiscal year alone, the management of osteoporosis and bone health in 
general is of great importance115. Strategies to improve bone health include osteoprotective 
behaviours such as weight-bearing physical activity that stresses bone and muscle as well 
as calcium and vitamin D intake42,45,47.  
Due to the increased risk of fracture in people with epilepsy, ideally this would be 
reflected in the population by an increase in the participation of osteoprotective 




behaviours. Two studies using Canadian Community Health Survey (CCHS) data have found 
either no difference or that people with epilepsy are less active than the general 
population71,72. One of these studies investigated Canadians aged 12–39 years old, 
excluding older adults who are more vulnerable to decreased bone health71, while the 
other investigated the entire survey population of Canadians aged 12 years and older72. 
Neither study differentiated between children and adults. 
This study investigates osteoprotective behaviours in the adult Canadian population 
with and without epilepsy using the 2010 CCHS and focusing on adults aged 50 and older 
who are particularly vulnerable to declining bone health. Weight-bearing activity is 
compared to a younger subgroup of adults (aged 18–49 years old) as a baseline to note 
changes in physical activity that occur with age and general decline in health (energy, 
mobility, strength) rather than due to epilepsy status. Motivation to exercise will also be 
evaluated as an underlying factor for actual participation. Unlike previous studies, this 
study will also consider food choices made based on calcium content or osteoporosis 





1. To investigate among those aged 50 and older with and without epilepsy, 
differences in osteoprotective behaviours: 
a. Weight-bearing physical activity 




i. Is there a difference compared to younger adults (aged 18–49)? 
ii. Is there a difference in motivation to exercise? 
b. Dietary choices related to bone health 
c. Vitamin D and calcium supplement use 
d. Sun exposure 
Secondary Objectives: 
2. To investigate, where possible, any gender differences in osteoprotective 
behaviours. 




The frequency of physical activity in older adults with epilepsy will be lower than that 
found in an analysis of the CCHS 2005 data (mean of exercising 82.5 times in three 
months)71, due an older subsample (50 years and older compared to 12–39 years old). 
Frequency of physical activity in individuals with epilepsy will be similar to or less than 
that of those without epilepsy, as has been found in an analysis of the CCHS 2005 data71 
and the CCHS 2003 data72. 
4.4 Methodology 
 
This study is a secondary database analysis of a cross-sectional survey. 
 






The CCHS is a cross-sectional survey that collects health-related data from 
Canadians aged 12 and over in all provinces and territories. The survey is calculated to be 
representative of 97% of the Canadian population aged 12 and over; as of 2007, the survey 
is conducted on an annual basis116. In the 2010 the Public Health Agency of Canada 
sponsored the addition of several questions, including epilepsy prevalence117,118. Moreover, 
the survey consistently addresses questions of nutrition, physical activity, sun exposure 
and fractures. Therefore the survey data collected from 2010 is of interest in examining the 
patterns of behaviours that are favourable to bone health in adults with epilepsy. 
The CCHS has been validated. Most of the CCHS variables originate from the 
National Population Health Survey (NPHS); this includes sections on physical activity, sun 
exposure and injuries117,119. The NPHS was developed through literature research and 
specialist consultation from Statistics Canada, Health Canada, provincial ministries of 
health and academic researchers. The NPHS questionnaire was approved by Statistics 
Canada and an Advisory Committee with representatives from provincial ministries of 
health, Health Canada, Public Health Agency of Canada, Statistics Canada and other 
government departments and specialists119.  
4.4.2 Data Extracted 
 
Data were extracted for adult participants (aged 18 and older). Forty-seven items 
from the CCHS survey was extracted. For a detailed list of variables and how they relate to 




the concepts of epilepsy, physical activity, sun exposure and bone-related dietary choices, 
see Appendix A (Table 9). For examples of wording of CCHS questions, see Appendix A 
(Table 10). Fracture data were also extracted as a bone health outcome. Demographic data 
(age and gender) were considered due to their independent effects on bone health74. 
Ambulatory status was considered for its potential limiting effects on other variables, 
particularly physical activity.  
4.4.3 Derived Variables 
 
Ambulatory status: Participants were considered non-ambulatory if they answered 
“no” to any one of questions 14 and 15 or “yes” to any one of questions 16–18 or 20 in the 
Health Utilities Index section of the survey (see Appendix A, Table 10). These items 
evaluated the participant’s mobility with questions asking if participants are usually able to 
walk around the neighbourhood without difficulty and without mechanical support, are 
able to walk at all, require the help of another person to walk or require a wheelchair.  
Frequency of weight-bearing activity: Activities included were walking for 
exercise, walking to work/school, popular/social dance, home exercises, ice hockey, ice 
skating, in-line skating, jogging, exercise class/aerobics, skiing/snowboarding, 
baseball/softball, tennis, weight-training, volleyball, soccer and basketball. Bicycling and 
swimming were excluded as they are not considered weight-bearing activities. Gardening, 
golfing and fishing were excluded due to tendency to be low-effort. The number of times 
participants reported engaging in these activities for the past 3 months was summed up. 




Duration of weight-bearing activity: For the weight-bearing activities above, 
participants reported the time interval spent each time when participating in the activity. 
Four time intervals were available to choose from with a ranking from 1 to 4: 1 indicated 
1–15 minutes spent on the activity, 2 indicated 16–30 minutes, 3 indicated 31 minutes to 1 
hour, 4 indicated more than 1 hour. Using these values, the mean of each participant’s total 
reported duration of time spent on weight-bearing activities was calculated; if a participant 
reported participating in more than one activity, the reported duration spent doing each of 
those activities would be averaged. Mean duration was then re-sorted into the four 
categories: 1 indicated mean scores of 1.00–1.99, 2 indicated 2.00–2.99, 3 indicated 3.00–
3.99 and 4 indicated scores of 4.00.   
4.4.4 Statistical Analyses 
 
Chi square, Mann-Whitney, Kruskal-Wallis, T-test and ANOVA were used to make 
comparisons between four subgroups: those aged 50 and older with epilepsy, those aged 
50 and older without epilepsy, 18–49 year olds with epilepsy, 18–49 year olds without 
epilepsy. Significance testing conducted on all four subgroups underwent further analysis 
to determine where significant differences were occurring; pairwise testing was used for 
Kruskal-Wallis and the Sheffe post-hoc analysis was used for ANOVA. Comparisons were 
made on the amount and duration of physical activity and sun exposure as well as the 
prevalence of bone-related dietary choices. The number of fractures were compared and 
were used as an outcome for regression modeling. Age, gender, physical activity and sun 
exposure were used as explanatory variables in a model for fracture occurrence to test if 
these osteoprotective behaviours are significant predictors of an actual bone health 




outcome. See Appendix I for full statistical analysis outline. All values presented are 
weighted by scaling the weights provided by Statistics Canada. No analyses had 




4.5.1 Baseline Demographics 
 
The CCHS 2010 sample consisted of an unweighted total of 56,210 adult 
participants (18 years and older) who responded to the questions concerning epilepsy. Of 
these 56,210 there were 318 adults with epilepsy, 161 of whom were aged 50 years and 
older. The prevalence of epilepsy in the CCHS 2010 sample was 0.6% for all adults, 0.6% for 
those 18–49 years old and 0.5% for those 50 years and older, which is within the 0.4%–
1.0% global prevalence range (Table 3)1.  The gender distribution among those 18–49 
years old with epilepsy was 51.7% male vs. 48.3% female and 47.9% male vs. 52.1% female 
for those without epilepsy; among those 50 years and older it was 43.0% male vs. 57.0% 
female for those with epilepsy and 49.9% vs. 50.1% for those without. The mean age of 
adults (18 years and older) with epilepsy was 42.78±16.63 years and without epilepsy was 
44.02±19.00 (mean ± standard deviation) years; for those 50 years and older the mean age 
was 59.30±9.34 years for those with epilepsy and 63.43±10.28 years for those without 
epilepsy (Table 3). 




There was no significant difference in the gender distribution between those with 
and without epilepsy (Table 3). Among those aged 50 years and older, people with epilepsy 
(PWE) were significantly (p<0.001) younger than those without in this sample. This 
significant difference did not exist in the younger subgroup of people aged 18–49 years old 
nor when the entire CCHS sample (aged 12 years and older) was analyzed. Among those 50 
years and older, there was no difference in ambulatory status between PWE and those 
without. However, between the ages of 18–49 years old, 7.9% of PWE were non-
ambulatory compared to 0.1% of those without epilepsy: this difference was significant 
(p<0.0001). 
Table 3.Demographics, CCHS 2010 














Gender (%)     
Male 51.7 47.9 43.0 49.9 
Female 48.3 52.1 57.0 50.1 
Age (years)     








% = Chi square, years = T-test, a = p<0.001 between groups 
 
4.5.2 Food Choices 
 
Although the CCHS does collect information on general vitamin and mineral 
supplement use, it does not collect information on calcium and vitamin D specifically. 
Dietary information collected is limited to fruit and vegetable consumption and dietary 
choices; dairy information is not collected. Our questions regarding vitamin D and calcium 




intake could not be answered.  Therefore dietary food choices were used as an indirect 
measure. Among those 50 and older, there was no significant difference between the 
proportion of PWE who made food choices based on calcium content or osteoporosis 
concern compared to those without epilepsy (Figure 3). 
Figure 3. Lifestyle behaviours in those 50 years and older, CCHS 2010 
 
Chi square, p = NS 
4.5.3 Sun Exposure 
 
Among those 50 and older, there was no significant difference in sun exposure 
between PWE and those without, as measured by time intervals spent in the sun. (Figure 
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Figure 4. Time spent in sun in a normal day by those 50 years and older, CCHS 2010 
 
Chi square, p = NS for all analyses 
 
4.5.4 Weight-bearing Activity – Participation 
 
Among those 50 and older there was no significant difference in reported 
participation in at least one weight-bearing activity in the past 12 months based on 
epilepsy status (Table 4). Among people without epilepsy who were 50 years and older, 
significantly (p<0.0001) more women reported participating in at least one weight-bearing 
activity than men. This difference was not observed among PWE who were 50 years and 
older. Among the 18–49 year olds there was no significant difference in reported 
participation in at least one weight-bearing activity in the past 12 months based on 



































None Less than 1 hour 1 hour to less than 3 hours 3 to 5 hours




analysis due to the higher amount of non–ambulatory people in the 18–49 year old PWE 
subgroup.  
Among those 18–49 years old, PWE reported participating in significantly (p<0.001) 
less types of weight-bearing activities than those without. However 18–49 year old PWE 
participated in significantly (p<0.025) more types of activities than their older 
counterparts. Similarly, among people without epilepsy, the younger subgroup participated 
in significantly (p<0.0001) more types of activities than the older subgroup. Although PWE 
50 years and older also participated in less different types of weight-bearing activities 
compared to people without epilepsy in the same age group this difference was not 
significant (Table 4).  
4.5.5 Weight-bearing Activity – Frequency 
 
Among those 50 years and older, PWE participated in weight-bearing activities 
significantly (p<0.001) less often in a 3 month period than those without epilepsy (Table 
4). Women with epilepsy who were 50 years and older reported participating in weight-
bearing activities significantly (p<0.020) more often than their male counterparts. 
Although among those without epilepsy the younger subgroup participated in weight-
bearing activities significantly (p<0.006) more often than the older subgroup, this 
difference was not observed among PWE.  
  











Number of Different 
Types of Activities 
Participated in 
(mean) 
Number of Times 
Participated in 
Activity in Past 3 
Months 
(mean) 
18–49 year olds    
With Epilepsy 87.3* 2.13a,b 74.68 
Without Epilepsy 88.5* 2.75a,c 82.71d 
50 years and older    
With Epilepsy 82.4 1.39b 57.42e 
Male 81.0 1.50 39.93h,i 
Female 82.9 1.27 74.69h 
Without Epilepsy 80.3 1.53c 76.46d,e 
Male 78.7f 1.51g 76.69i 
Female 81.7f 1.55g 76.26 
Within group percentages shown in parentheses, % = Chi square, mean = ANOVA, * = non-ambulatory 
people were excluded from analysis, a = p<0.001 between groups, b = p<0.025, c = p<0.0001, d = 
p<0.001, e = p<0.001, f = p<0.0001, g = p<0.029, h = p<0.020, i = p<0.0001 
4.5.6 Weight-bearing Activity – Duration 
 
Duration of activity was measured in ordinal categories and participants who 
engaged in more than one activity would have more than one value for duration (one per 
each reported activity), therefore means of these values were calculated and re-sorted into 
the original categories. Before investigating each category, overall means between those 
with and without epilepsy were compared to determine if there were any significant 
differences. Among those 50 and older, overall PWE were on average significantly 
(p<0.011) more likely to participate in weight-bearing activities for shorter time intervals 
per session than those without epilepsy, scoring 2.20 out of 4 compared to 2.40 out of 4. 
Upon finding this difference, further investigation was conducted to ascertain in which 
time interval category or categories this difference was apparent. We found that 
significantly (p<0.002) more PWE reported to 16–30 minutes of exercise than those 
without epilepsy while significantly (p<0.013) less PWE reported to more than one hour of 




exercise than those without epilepsy (Figure 5). Among those without epilepsy who were 
50 years and older, men reported participating in weight-bearing activities for significantly 
(p<0.0001) longer time intervals than women, scoring 2.42 out of 4 compared to 2.31 out 
of 4; this difference was not significant among PWE in the same age group with men 50 and 
older with epilepsy scoring 2.23 out of 4 and women 50 and older with epilepsy scoring 
2.16 out of 4. Among those without epilepsy, the younger subgroup participated in weight-
bearing activities for significantly (p<0.0001) longer time intervals than the older 
subgroup, scoring 2.46 out of 4 compared to 2.36; this difference was not significant within 
PWE with 18–49 year olds scoring 2.44 out of 4 compared to those 50 and older scoring  
2.20. 
  




Figure 5. Average time spent participating in weight-bearing activity per session by those 50 years and 
older, CCHS 2010 
 




There was no significant difference in PWE 50 years and older who reported having 
a barrier (such as illness) that prevented them from improving their health as compared to 
those without epilepsy in the same age subgroup (Figure 6). There was no significant 
difference based on epilepsy status in the proportion of people who reported believing that 
they should improve their physical health (73.9% of PWE vs. 63.6% without epilepsy) or in 
those who reported doing something to improve their physical health in the past 12 
months (65.2% vs. 54.8%) or in those who reported intending to do something to improve 
their physical health in the next year among those 50 years and older (87.5% vs. 74.6%). 
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who reported that they thought increasing exercise is the most important thing they should 
do to improve their health (68.8% of PWE vs. 55.9% of those without) or who reported that 
exercising more was the most important thing they did to improve their health in the past 
12 months among those 50 years and older (35.7% vs. 49.9%). However, among this older 
age group significantly (p<0.015) fewer PWE reported that they intended to exercise more 
in the next year to improve their health as compared to those without epilepsy (38.5% of 
PWE vs. 71.2% without epilepsy).  
Figure 6. Motivation to improve health in those 50 years and older, CCHS 2010 
 




















































































With Epilepsy Without Epilepsy




There was no significant difference in fracture occurrence based on epilepsy status in 
either age subgroup (Figure 7). However, when considering the entire adult (18 years and 
older) population, a significantly (p<0.042) higher number of PWE reported having a 
fracture in the past 12 months as compared to people without epilepsy.  
Figure 7. Proportion that reported a fracture in the past 12 months, CCHS 2010 
 




Consistent with the reports of higher risk of fracture among people with epilepsy, this 
study found that in the 2010 CCHS survey among adults (aged 18 years and older) 
significantly more PWE reported experiencing a fracture in the past 12 months than people 
without epilepsy though the higher number of fractures in PWE was not significant when 
looking only at those aged 50 and older. A retrospective matched cohort study conducted in 
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Manitoba looking specifically at osteoporotic fractures in individuals aged 50 and older 
with a larger sample size (79 cases of PWE with a fracture compared to 6 cases of PWE 
with a fracture in this study) found that individuals with an osteoporotic fracture were 
significantly more likely to have epilepsy and that use of the AEDs carbamazepine, 
clonazepam, gabapentin, phenobarbital and phenytoin, regardless of epilepsy status, were 
all significantly associated with osteoporotic fracture120. Considering the small sample size 
of PWE and the low number of reported fractures in our study, it is unsurprising that a 
significant difference is not observable when the population is broken into subgroups. 
This study investigated several osteoprotective behaviours among those aged 50 and 
older that may impact fracture occurrence to determine if there was a difference in these 
behaviours between PWE and those without epilepsy in this especially vulnerable older 
group. Some differences became apparent from an in depth analysis of physical activity, 
specifically the weight-bearing type which is beneficial to bone. No significant differences 
in osteoprotective food choices or sun exposure were found among those aged 50 and 
older. 
Despite there being no significant difference in the proportion of people who 
participated in any weight-bearing activity regardless of epilepsy status, there were 
differences in the number of different types of activities people participated in, how often 
they participated in these activities over 3 months and how long they spent on these 
activities per session. Older adults (50 years and older) with epilepsy typically engaged in 
weight-bearing activities less often and for shorter duration than older adults without 
epilepsy. Older men with epilepsy reported participating in weight-bearing activities less 




often, not only than men without epilepsy, but also than women with epilepsy. Younger 
adults (aged 18 to 49 years old) reported more variety in the weight-bearing activities they 
participated in compared to their older counterparts, but those with epilepsy showed 
significantly less variety than those without. On the other hand, while in the general 
population younger adults unsurprisingly participated in weight-bearing activities 
significantly more often and for significantly longer duration than their older counterparts 
this was not observed among PWE. Overall, older adults with epilepsy appeared to be less 
active than older adults without epilepsy and this overall pattern was not observed in 
younger adults (excluding a tendency for less variety in the weight-bearing activity choice 
of younger PWE).  
A previous study examining Canadians aged 12 years and older found that those with 
epilepsy were less active than the general population while a study examining those aged 
12–39 years old did not: our findings may explain this disagreement, suggesting that this 
difference in physical activity may be more pronounced in the older age range. Women 
with epilepsy who are at increased risk of fracture not only due to epilepsy status but due 
to their biological sex do appear to participate in higher amounts of physical activity than 
men with epilepsy. This could be indicative of a gender bias in the education on bone health 
awareness; an intervention study conducted on 2,438 people found that women scored 
higher than men on an osteoporosis knowledge test both before and after an educational 
intervention121,122. However, the same pattern is not observed in those aged 50 and older 
without epilepsy and, in fact, women with and without epilepsy participate in a similar 
amount of physical activity as men without epilepsy. This suggests that rather than women 
with epilepsy being more active it is a case of men with epilepsy being less active. 




Other studies have found patients with epilepsy to be less active and less physically 
fit than the general population123–125.  One study investigating patients with epilepsy 
between 5–17 years of age and their non-epileptic siblings found that the patients with 
epilepsy to be less active, significantly so in those 13–17 years old when comparing 
number of hours spent in group sports and total sports125. In the 13–17 age group, 
significantly more parents of patients with epilepsy reported their children as being “less 
active than they would like” as compared to sibling controls; parents of 61% of the patients 
with epilepsy cited “laziness or lack of interest in exercising” as a reason for their child’s 
perceived lack of activity as compared to 31% for controls125. A non-significant association 
between increased seizure frequency and less sports activity was found in all patients125. 
The lower sports activity observed in patients with epilepsy in the more autonomous age 
group of 13–17 years as compared to 5–12 years may demonstrate teenagers with epilepsy 
forming their own personal exercise habits that could persist into adulthood. A cohort-
matched control study of 100 adults with a mean age of 36.5 years and with recurrent, 
unprovoked seizures since childhood without associated initial neurological impairment or 
disability did not find a significant difference in frequency of exercise in those with epilepsy 
compared to controls however they did find that those with epilepsy were significantly less 
physically fit as measured by several muscle-power tests126. Though frequency of exercise 
was investigated, duration of exercise was not which may explain discrepancies between 
exercise frequency and physical fitness.  
In the past, people with epilepsy were cautioned against physical activity which may 
in part explain the trend of less exercise and lower physical fitness than their non-epileptic 
counterparts. The American Medical Association Committee on Medical Aspects of Sports 




encouraged avoidance of both collision sports and non-contact sports in people with 
epilepsy in 1968123,127. However by 1997 the International League Against Epilepsy was 
recommending that only skydiving and scuba diving should be avoided by people with 
epilepsy123,128. There is little evidence that exercise induces seizures in PWE or that the 
repetitive minor head trauma that may occur during contact sports worsen seizure 
frequency or severity123. There is evidence that exercise can improve mental and social 
functioning in PWE124,129–132 and that restricting participation in sports can be emotionally 
distressing129,133. 
In our study the lower level of physical activity seen in older PWE did not appear to 
be associated with self-perceived barriers among PWE because self-report of having a 
barrier to improving health was similar between PWE and those without epilepsy. It is 
possible that this item in the CCHS does not have the nuance to examine the relationship 
between epilepsy and exercise habits but ours is not the only study to find this. A previous 
study investigating physical activity in 176 adults with epilepsy found that of the 22% of 
patients with epilepsy who reported reducing physical activity in the previous year due to 
illness (as compared to 24% of matched controls), only 2% cited epilepsy as the reason126.  
There was also no observed association between continuation of seizures, AED use or self-
perceived health with physical activity in patients with epilepsy126. 
  In this study, the proportion of older PWE who reported increasing their exercise to 
improve their physical health in the past 12 months and believing that they should increase 
their exercise to improve their physical health was not significantly different compared to 
the general population, however significantly less PWE had the intention of increasing their 




exercise in the next 12 months. This suggests a lack of motivation to exercise not caused by 
perceived inability to exercise nor by the belief that more exercise is unnecessary. A study 
in children with epilepsy did find a non-significant association between higher seizure 
frequency and less sports activity125. Epilepsy concern influencing exercise behaviours in 
childhood that persist in adulthood, though epilepsy concern during physical activity may 
be less salient, is a possible theory. Our study observed less physical activity in younger 
PWE aged 18–49 than their non-epileptic counterparts though the difference was only 
significant between PWE aged 50 and older and their non-epileptic counterparts. Further 
investigation into motivation to exercise in individuals with epilepsy is necessary to 
understand the lower physical activity seen in people with epilepsy and to examine the 
gender difference found in this study. The motivation findings in this study suggest that 
lower exercise is not due to a lack of knowledge on the benefits of exercise and thus may 
not be improved by increased education as PWE were similar to those without epilepsy in 
thinking that they should exercise more to improve their physical health. Gender analysis 
on motivation could not be completed due to low sample size of PWE. 
Though older PWE are at an increased risk of fracture, their dietary choices based 
on calcium content and osteoporosis concern were similar to older adults without epilepsy. 
Sun exposure, the main source of vitamin D, was also similar between older PWE and those 
without epilepsy. A study administering the Osteoporosis Knowledge Test in 94 patients 
with epilepsy with a mean age of 45 found that knowledge scores on calcium and exercise 
were lower than that found in previous studies on the general population134. This lower 
osteoprotective knowledge may explain our findings and, overall, this may be indicative of 
a lack of knowledge on the increased risk of bone disease associated with epilepsy. 




There were limitations in this study due to the use of the CCHS which is a survey on 
general health and not focused specifically on bone disease or epilepsy. Data were not 
collected for the use of vitamin D or calcium supplements and calcium dietary intake was 
not investigated therefore the measurement of these osteoprotective behaviours in this 
analysis was indirect. The small sample size of adults with epilepsy also limited our 
analysis, particularly low fracture occurrence within the past 12 months as well as the low 
response rates on questions regarding sun exposure and dietary choices. Future research 
investigating vitamin D and calcium intake in older adults with epilepsy is necessary. 
Despite these limitations, this study did find that, though they face an increased risk 
of bone disease, the application of osteoprotective behaviours in older adults with epilepsy 
is similar or lower than older adults without epilepsy. Motivation to exercise in adults with 
epilepsy merits further investigation, especially considering the psychosocial benefits of 
physical activity in PWE as well as the osteoprotective benefits.  
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AEDs are thought to compromise bone health in people with epilepsy and so the 
application of osteoprotective behaviours such as physical activity and calcium and vitamin 
D intake in this population is of interest, especially in those aged 50 and older who are even 
more vulnerable to metabolic bone disease74,75. There is research investigating physical 
activity in people with epilepsy and nationwide data on physical activity in Canadians with 
epilepsy is available71,72. However, vitamin D and calcium intake information in people with 
epilepsy is not as prevalent. The association between enzyme-inducing AEDs and 
decreased bone health is thought to function via a decrease in serum vitamin D; a 
systematic review on the effect of vitamin D treatment on bone health in adults with 
epilepsy found some evidence for beneficial effects but was lacking in conclusions on 
optimal dosing and so information on vitamin D intake in adults with epilepsy is 
particularly important. Other studies have gauged vitamin D and calcium supplementation 
in adults with epilepsy to be from as high as 25.4% in adults with a mean age of 41.9 years 
to as low as 4.9% in a veteran population with a mean age of 55.7 years66,67. The prevalence 
of vitamin D supplementation in Canadian adults aged 50 and older with epilepsy is not 
known. Differences in vitamin D supplementation based on AED type (enzyme-inducing vs. 
non-inducing) in older Canadian adults is not known. Finally, a survey in Norway on 
women aged 16–42 years being treated for epilepsy found that 88% of those who were 




taking AEDs known to interact with bone metabolism were not aware of this adverse 
effect65. This study did not consider adults aged 50 and older and excluded men.  
Our study will aim to fill in these gaps in information regarding supplementation in 
older Canadian adults with epilepsy as well as the awareness of the association between 




1. To determine the prevalence of vitamin D supplementation in Canadian adults aged 
50 and older with epilepsy and to investigate if there is a difference based on type of 
AED(s) being used or based on gender.  
Secondary Objectives: 
2. To determine the total vitamin D intake via diet and supplements in Canadian adults 
aged 50 and older with epilepsy 
a. Is there a difference based on type of AED(s) being used? 
b. Is there a difference based on gender? 
3. To conduct an exploratory analysis of the awareness of the association between 
AEDs and decreased bone health in Canadian adults aged 50 and older with epilepsy 
a. Is there a difference based on type of AED(s) being used? 
b. Is there a difference based on gender? 






The prevalence of vitamin D supplementation in older adults with epilepsy will be 
comparable to the 4.9% found in a previous study66. 
5.4 Methodology 
 
5.4.1 Study Design 
 
An epidemiological cross-sectional survey was designed to investigate several 
aspects of bone health in older adults with epilepsy, including: vitamin D supplement use, 
calcium supplement use, dietary vitamin D intake and osteoporosis/osteopenia diagnosis. 
Due to the involvement of human participants, this research has been approved by the 
University of Waterloo Research Ethics Board. 
3.3.2 Questionnaire 
With permission, a survey by Fedorenko and colleagues was used as a foundation 
for the survey design67. Details on epilepsy treatment will be collected: current and past 
AED use, type of AED(s), dose and duration. Questions probing the awareness of bone 
health and the increased risk of bone disease associated with AEDs are included. The type 
of data being collected is observational and are largely prevalence values and so do not 
necessitate intervention study designs or longitudinal designs. A survey is ideal as the ease 
of study design and data collection is optimized.  




The survey used by Fedorenko and colleagues was designed by adopting items from 
validated surveys (National Health and Nutrition Examination Survey (NHANES), 
Behavioral Risk Factor Surveillance System (BRFSS) questionnaire) and previously 
published articles. In this project the survey has been modified by modeling questions on 
supplementation and dietary intake more closely to those from the validated source 
(NHANES)135,136.  Additional questions to be investigated that were not addressed by 
Fedorenko, Wagner & Wu to probe the awareness of the association between AEDs and 
bone loss and if this association has been brought to attention by the participants’ 
doctor(s) were created. The questionnaire consists of 15 items, with 4 additional questions 
included in the online version (see Appendix B, Figure 8).  
3.3.3 Survey Validation 
The survey largely consists of adopted items from previously validated surveys. Co-
investigators provided feedback on clarity, comprehensibility and precision of items which 
were incorporated in the final design. 
5.4.2 Sample Size 
 
Using the 4.9% prevalence of vitamin D and calcium supplement use in people with 
epilepsy found by Espinosa and colleagues66, a 95% confidence interval and a standard 
error of 0.05, in order to accurately determine the proportion of older adults (≥50 years 
old) with epilepsy who take vitamin D supplements, a sample of at minimum 72 
participants must be recruited (see Figure 9). Sample size was calculated using a formula 
for estimating the proportion of a binary outcome in a descriptive study137. 




Formula 1. Sample size calculation 











Vitamin d prevalence is 𝑝 = 0.049 and therefore 1 − 𝑝 = 0.951 
Absolute standard error is 𝑑 = 0.05 
𝑛 =  
1.962 × 0.049 × 0.951
0.052
 
𝑛 ≅ 72 
 
5.4.3 Participant Recruitment 
Inclusion Criteria 
This study is investigating both male and female older adults (aged 50 years and 
above) with self-identified epilepsy or seizure disorder. Participants should have past or 
present AED use. 
Exclusion Criteria 
Individuals who are unable to provide informed consent will be excluded from this 
study. Ability to consent may be impaired in non-English speakers without translators and 
in individuals with cognitive impairment. Exclusion of non-English speakers without 
translators and of individuals with cognitive impairment is also to improve reliability of 
answers by limiting the possibility of a lack of comprehension of survey questions. 
Potential participants have been invited to participate in the survey through 
epilepsy support organizations: Epilepsy South Central Ontario and the Canadian Epilepsy 




Alliance. Recruitment flyers have been posted in public spaces such as libraries and grocery 
stores as well as independent living facilities and on social media. Individuals with epilepsy 
from previous studies have been contacted for participation. See Appendix B, Figure 10 for 
recruitment protocol. 
5.4.4 Survey Administration 
 
The survey has been made available via several routes: internet, mail and telephone. 
The primary route of administration is online hosted by SuveyMonkey. This is because 
targeted recruitment via epilepsy organizations is mainly facilitated by the internet (e.g. 
recruitment emails, social media). Potential participants have been invited to contact the 
researchers to arrange to complete the survey using an alternate method (telephone, mail). 
Online consent is obtained by participants choosing to open the survey link; phone surveys 
require verbal consent and mailed surveys had signed consent. Information and feedback 
letters with study details, confidentiality and ethical statements are included as part of the 
survey package in online and mailed administration and for phone surveys is both verbally 
conveyed and sent to participants via email, fax or mail. ID numbers have been assigned to 
participants; separate ID number classifications are used for each route of administration. 
ID numbers are linked to completed surveys. 
The study is ongoing; data is currently being collected. 
5.4.5 Statistical Analysis 
 




Descriptive statistics on prevalence of vitamin D supplement use and vitamin D dietary 
intake will be reported. Regression modeling for vitamin D supplement use as a response 
incorporating the explanatory factors age, gender, epilepsy medication and seizure 
frequency will be completed if sample size and response rates allow. Self-reported 
osteoporosis will be controlled for.  See Appendix J for full statistical analysis plan. 
6 Conclusion 
 
6.1 Management of bone health in people with epilepsy 
 
It is well established in the literature that many AEDs have been linked to decreased 
bone health15,22,138. A management plan for this adverse effect associated with AEDs has not 
established. Management of age-related bone loss in the general population can be used as 
a basis for management of AED-related bone loss; weight-bearing exercise as well as 
calcium and vitamin D intake are recommended non-pharmacological osteoprotective 
behaviours42–45. Typically age-related bone loss becomes a salient issue at ages of 50 years 
and older74,75, therefore adults with epilepsy 50 years and older have an accumulation of 
risk for bone loss that is of particular concern.  
6.2 Exercise as an osteoprotective measure in people with epilepsy 
 
An analysis of the 2010 CCHS data found that adults with epilepsy participate in 
weight-bearing physical activity less often than adults without epilepsy and that this 
difference is significant in those 50 and older. PWE 50 and older also participate in weight-




bearing activities for significantly shorter duration than those 50 years and older without 
epilepsy. This is in agreement with previous research that has found people with epilepsy 
to be less active and less physically fit72,124–126.  
It is worth noting that there older adults were less active as compared to younger 
adults, regardless of epilepsy status in the CCHS 2010 data. This phenomenon is also 
evident in the literature139–142. A review on 38 intervention studies on physical activity in 
adults with a minimum age of 40 years and an average age of 50 years and older found 
little evidence on long-term effectiveness143. 
In the 2010 CCHS data, a significantly larger proportion of people with epilepsy 50 
years and older reported having no intention to increase their exercise to improve their 
physical health as compared to those 50 years and older without epilepsy. Due to AED use, 
people with epilepsy have an additional risk of decreased bone health. Their participation 
in the osteoprotective behaviour of exercise, however, does not correspond to this 
increased risk and, in fact, is lower than the general population.  
Considering the previous, now defunct, warnings against exercise in people with 
epilepsy, while the 2010 CCHS data show that people with epilepsy 50 years and older do 
not report significantly more self-perceived barriers to improving their health than those 
without epilepsy, the reasoning behind lower levels of exercise in people with epilepsy is 
unclear. Moreover, as the 2010 CCHS data shows that people with epilepsy 50 years and 
older are similar in their belief that they should increase their exercise to improve their 
health to those without epilepsy, it appears that any programs to education and/or engage 
people with epilepsy with the goal of increasing exercise in this population would require 




nuance and a thorough understanding of the underlying relationship between exercise and 
epilepsy status. More research is necessary to delineate this relationship. 
6.3 Calcium and Vitamin D as an osteoprotective measure in people with epilepsy 
 
According to the NHANES survey of 2003–2006, 8–22% of 4061 adults 51 years and 
older were reaching adequate intake of calcium via their diet and 1–7% of 1924 adults 51 
years and older were reaching adequate intake of vitamin D via their diet69. There was a 
clear trend in both calcium and vitamin D dietary intake showing that with increasing age, 
the amount of people reaching adequate intake levels decreased69.  
Supplementation is a convenient, feasible method of improving intake levels of these 
vital nutrients; data from the 2007–2009 Canadian Health Measures Survey in 5306 
Canadians aged 6–79 years old found that vitamin D supplement users had significantly 
higher serum vitamin D concentrations than non-users68. In the general population, the 
prevalence of regular (5 years or more) calcium supplementation was found to be 
approximately 33% in a survey of 100,196 people aged 45–75 years old144. In the NHANES 
survey of 2003–2006, of 20,470 Americans aged 1 year and older, 43% reported using 
calcium supplements and this number increased to 51%–67% when considering only those 
aged 51 years and older; use of vitamin D supplements was 37% in those aged 1 year and 
older and this number increased to 40%–49% when considering only those aged 51 years 
and older69.  
In comparison, there are very little data on calcium and vitamin D intake, via diet or 
supplementation, in people with epilepsy. Two studies that investigated both calcium and 




vitamin D found that prevalence of supplementation in adults with epilepsy was 4.9% and 
25.5% in samples with mean ages of 55.7 and 41.9 years respectively. Though these 
prevalence percentages are very different, they are both lower than those found in the 
general population. The CCHS 2010 cycle received low response rates for questions on 
dietary choices related to osteoporosis concern or calcium content and for sun exposure; 
using these indirect measures of calcium and vitamin D intake it was found that there was 
no significant difference between older adults with and without epilepsy. 
6.4 Challenges with managing bone health in people with epilepsy 
 
Along with the previously mentioned decline in physical activity with increasing age 
seen in all adults, regardless of epilepsy status, the relationship between epilepsy and 
motivation to exercise is not yet understood. It is possible then that the programs that exist 
to encourage physical activity in older adults may not be as effective in older adults who 
have epilepsy. Moreover, interventions in older adults without epilepsy have not shown 
strong evidence for adherence in the long-term. Targeting this osteoprotective behaviour 
to manage bone health in people with epilepsy, particular older adults, may require 
additional nuance. 
In comparison, calcium and vitamin D supplementation may be a more convenient 
and feasible route. Of the AEDs that have been linked to detrimental effects on bone, the 
majority are enzyme-inducing and have been associated with decreased biologically active 
vitamin D. As vitamin D intake is already considered to be osteoprotective, this evidence-
based connection to AEDs that are commonly used by people with epilepsy makes it 




particularly appealing for managing the adverse effect of decreased bone health in people 
with epilepsy. 
A systematic review on the effect of vitamin D supplementation on bone health in 
adults with epilepsy had overall positive findings in the studies reviewed, though there was 
a lack of standardized procedures. Previous research in the general population has found 
that recommended doses of vitamin D are too low to see an effect on fracture outcome; the 
systematic review did not provide any clarity on the issue of optimal vitamin D dosing 
regimen. This serves as an obstacle towards developing a standardized management plan 
for bone health in adults with epilepsy. 
A ubiquitous challenge when facing the management of any adverse effect is 
awareness. Regardless of choice of osteoprotective measure, one needs to be aware that 
the potential for bone loss exists in order to confront it. The negative effect on bone 
associated with many AEDs has been researched as early as the 1960s15. However few 
epilepsy treatment guidelines make note of this adverse effect10,56,57 and a study conducted 
in an area that did have local recommendations of vitamin D and calcium supplementation 
for women taking enzyme-inducing AEDs found that less than 5% of the women taking 
enzyme-inducing AEDs were informed of this65. 
A currently ongoing cross-sectional study of original design will aim to fill in the 
challenges caused by gaps of knowledge stated here. Prevalence of vitamin D 
supplementation specifically, rather than in combination with calcium, will be determined 
in older adults with epilepsy. Dosing of vitamin D in this population will be investigated. 
Prevalence of calcium supplementation as well as dietary intake of vitamin D will also be 




investigated. Finally, an exploratory analysis of awareness of the adverse bone health effect 
associated with some AEDs in older adults with epilepsy will be conducted; this will 
consider both the awareness of the adverse effect as well as the source of the awareness 
(such as family doctor, friends, family, their own research).  
7 Implications 
 
This research has explored several aspects of bone health in people with epilepsy and 
the findings have both provided information to guide research and highlighted gaps in 
knowledge. The finding that the lower physical activity seen in people with epilepsy does 
not appear to be related to self-perceived barriers suggests that further research is needed 
to explore the reasoning behind lower physical activity in people with epilepsy. Findings 
from the systematic review suggested that there is some beneficial effect of 
supplementation on bone health outcomes in adults with epilepsy but that optimal dosing 
regimen is unknown and that methodology was heterogeneous, motivating further 
research into this area. Findings from the upcoming original survey will provide 
information on the prevalence of vitamin D supplementation in older adults with epilepsy 
as well as what doses are typically being used. Comparing these findings to prevalence of 
supplementation in the general population as well as recommended doses in the general 
population will allow a deeper understanding of the degree of participation in this 
osteoprotective behaviour by people with epilepsy. Information on if people with epilepsy 
are aware of the adverse bone health effect associated with many AEDs along with where 
they are getting this information from will help to guide any future efforts to improve 
education and awareness on this topic.   
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Appendix A – Database keywords and search terms  
Database Keywords Search terms Limitations 





Cochrane Trials  epilepsy; vitamin D  
Embase Bone Density; Bone Strength; 
Osteoporosis; Osteopenia; 
Osteomalacia; Bone Disease; 
Epilepsy; Anticonvulsive 
Agent; Vitamin D; 
Ergocalciferol; Colecalciferol 





EU Clinical Trials 
Register 




Epilepsy (medical condition)   
International 
Pharmaceutical  
Epilepsy epilep*; anticonvulsant; 






Medline Bone Density; Osteoporosis; 
Bone Diseases, Metabolic; 
Epilepsy; Anticonvulsants; 
Vitamin D; Ergocalciferols; 
Cholecalciferols;  
bone adj2 health*; 
osteopenia; epilep*; 
calciferol 
Humans; All adults 
PubMed  epilepsy; vitamin D Human; Clinical 





Scopus  epilepsy; vitamin D Articles; Adult; 
exclude book source 
 
  




Appendix B – Search phrases for a systematic search using Google  
Search # Search phrase 
1 epilep AND “vitamin d” AND ~trial AND ~supplement AND -children 
2 epilepsy AND ergocalciferol AND ~trial AND -children 
3 epileptic AND “vitamin d” AND -children AND bmd 
4 ~epilepsy AND ~bone AND ergocalciferol AND intervention 
5 epilep AND ~osteoporosis AND calcitriol AND ~intervention 
6 ~epileptic AND osteoporosis AND ergocalciferol 
7 epilepsy AND bmd AND ~trial AND ~ergocalciferol 
8 “epilepsy” AND “vitamin d” AND ~bone AND -children 
9 aed AND “vitamin d” AND bmd 
10 ~aed AND ~ergocalciferol AND ~bone AND -children 
 
  




Appendix C – Summary of included studies  






































Hoikka et al., 
1982 












et al., 2010* 




400 25-OHD 25-OHD, ALP, 
calcium 
Mikati et al., 
2005 

















Europe QE 20 
9 
months 
















Pedrera et al., 
2000 










Sherk & Snape, 
1977 











*studies with a calcium control for both the placebo and treatment arms, # measured after 3 months 
instead of full 6 months, Ad-SOS = Amplitude-dependent speed of sound ultrasound, ALP = alkaline 
phosphatase, BMC = bone mineral content, BMD = bone mineral density, CBZ = carbamazepine, CLN = 
clonazepam, GB = gabapentin, LTG = lamotrigine, PB = phenobarbital, PH = phenytoin, PR = primidone, 
PTH = parathyroid hormone, QE = quasi-experimental study, RCT = randomized controlled trial, TP = 
topiramate, VPA = valproate84–92 


















Representativeness 2 2 2 2 2 
Sample size power 1 2 2 2 1 
Confounder adjustment 1 2 3 2 3 
Appropriate statistics use 3 3 3 3 3 
Treatment of missing data 





measurements stated and 
appropriate 
3 3 3 3 2 
Objective assessment of 
outcomes 
2 2 2 2 2 
Total (out of possible 21) 14 16 18 16 13 
0=definitely no, 1=mostly no, 2=mostly yes, 3=definitely yes, Not verified=not explicitly stated in study 
85,86,89,91,92 
  








et al., 1973 
Krishnamoorthy 




et al., 1977 
Adequate generation of allocation 
sequence 
1 1 1 1 
















Incomplete data adequately addressed 1 1 1 1 
No selective outcome reporting 1 1 1 1 
No other problems that would lead to 
high risk of bias 
1 1 1 1 
Total (out of possible 6) 5 4 5 4 
0=high risk of bias, 1=low risk of bias, Not verified=not explicitly stated in study84,87,88,90 
 
  




Appendix F – Description of outcomes measured in included studies  
Outcomes measured Description 
Alkaline phosphatase (ALP) A bone turnover marker, ALP is a marker of bone formation. 
The normal range of ALP varies by age and gender; bone 
diseases may cause elevations in ALP101 
Amplitude-dependent speed of sound 
(Ad-SOS) ultrasound 
Bone health was approximated by ultrasound of the non-
dominant hand in one study91. Larger speed of sound 
measurements indicate higher bone density. 
Biopsy Two studies used quantitative morphometric analyses of 
biopsies to study bone quality in subjects86,89. Examining a 
participant’s bone sample under microscope can allow insight 
into the microarchitecture of bone, such as level of calcification. 
Bone mineral content (BMC) A measure of bone density using bone mass per area measured. 
The study that measured BMC used single photon 
absorptiometry (SPA)84. 
Bone mineral density (BMD) A measure of bone density using BMC divided by weight. The 
studies that measured BMD used dual x-ray absorptiometry 
(DXA)88and the Am-241 gamma ray attenuation method86. 
Forearm bone mass One study approximated bone health by measuring bone mass of 
the forearm85. 
Inorganic phosphate/phosphorous A bone turnover marker; high inorganic phosphate levels can 
decrease bone resorption145. 
Parathyroid hormone (PTH) A bone turnover marker; elevated PTH is associated with 








Appendix G – Items to be extracted from CCHS 2010 questionnaires117 
Concept CCHS Variable(s) Variable Codes 
Epilepsy Neurological Conditions NEU_Q030 – Q033 
Lifestyle behaviours 
beneficial to bone health 
Physical Activities 
Sun Safety Behaviours 
Food Choices 






detrimental to bone health 
Smoking 
Alcohol Use 













Fractures, broken bones Injuries INJ_Q01; INJ_Q02; INJ_Q05; 
INJ_Q06 
Ambulatory status Health Utility Index HUI_Q14–HUI_Q18; HUI_20 
Demographics Height and Weight  





ANC_Q03; HWT_Q1; SDC_Q1; 
SDC_Q4; SDC_Q4_1; SDC_Q4_3 
 
  








ANDB_Q01 What is [respondent name]’s age? 
SEX_Q01 Is [respondent name] male or female? 
ANC_Q03 What is your age? 
CIH_Q1 In the past 12 months, did you do anything to improve your health? (For example, lost 
weight, quit smoking, increased exercise 
CIH_Q2 What is the single most important change you have made? 
CIH_Q3 Do you think there is anything you should do to improve your physical health? 
HUI_Q14 Are you usually able to walk around the neighbourhood without difficulty and without 
mechanical support such as braces, a cane or crutches? 
HUI_Q15 Are you able to walk at all? 
HUI_Q16 Do you require mechanical support such as braces, a cane or crutches to be able to walk 
around the neighbourhood? 
HUI_Q17 Do you require the help of another person to be able to walk? 
HUI_Q18 Do you require a wheelchair to get around? 
HUI_Q20 Do you need the help of another person to get around in the wheelchair? 
FDC_Q1D (Do you choose certain foods or avoid others:) ...because you are concerned about 
osteoporosis (brittle bones)? 
FDC_Q2C (Do you choose certain foods because of:) ...the calcium content? 
PAC_Q1 Have you done any of the following in the past 3 months, that is, from [date three months 
ago] to yesterday? 
PAC_S1V What was this activity? 
PAC_Q2N In the past 3 months, how many times did you [participate in identified activity]? 
PAC_Q3N About how much time did you spend on each occasion? 
PAC_Q7 Other than the times you already reported walking for exercise, was there any time in the 
past 3 months when you walked to and from work or school? 
PAC_Q7A How many times? 
PAC_Q7B About how much time did you spend on each occasion? 
SSB_Q01 In the past 12 months, has any part of your body been sunburnt? 
SSB_Q06 About how much time each day do you spend in the sun between 11 am and 4 pm? 
INJ_Q01 Not counting food poisoning, in the past 12 months, that is, from [date one year ago] to 
yesterday, were you injured? 
INJ_Q05 What type of injury did you have? For example, a broken bone or burn. 
NEU_Q030 Do you have epilepsy? 
 
  













What percent of our sample 






What is the gender 








What is the age distribution of 




Age Epilepsy status 
18–49 











Is there a difference in the 
number of people who have 
or have not participated in a 
physical activity at all 
between PWE and those 
without? 
And is there a difference 
between adults under 50 and 
those over 50? 
Frequency 









Have or have not 
participated in a 
physical activity 
Is the amount of physical 
activity that PWE or without 
epilepsy participate in 
similar? And is there a 
difference between adults 











Amount of physical 
activity (interval/ratio) 
participated in for the 
past 3 months 
Is the amount of physical 
activity that PWE or without 
epilepsy participate in 
similar? 
And is there a difference 











Amount of physical 
activity (interval/ratio) 
participated in for the 
past 3 months 
    
Is the duration of physical 
activity that PWE or without 
epilepsy participate in 
similar? 
And is there a difference 
between adults under 50 and 












Amount of time 
interval (ordinal) spent 
on physical activity. 
Is the amount of physical 
activity that PWE or without 
epilepsy participate in 
similar? 












Amount of time 
interval (ordinal) spent 
on physical activity. 




between men and women? 
    
Is the rate of dietary choices 
based on osteoporosis 
concern similar between PWE 








due to osteoporosis 
concerns 
Is the rate of dietary choices 
based on calcium content 









due to calcium content 
Is the motivation to improve 
health similar between PWE 







Intends to/does not 
intend to improve 
health 
Is the amount of fractures 








Had a fracture in the 








Appendix J – Statistical analysis plan for Vitamin D intake among older adults with 
epilepsy survey 
Question Variables Analysis 
Demographics/Descriptives of sample 
What is the average age? Age Mean 
What is the gender distribution? Gender Chi square 
What is the average age of first seizure? Age of first seizure Mean 
What is the average frequency of seizure? Seizure frequency (monthly) Mean 
What is the average number of years on AED 
medication? 
AED history Mean 
Research questions 
Is there a difference in AED type (inducer vs. 




Is there a difference in AED type (inducer vs. 




Is there a difference in AED type (inducer vs. 
non-inducer) based on seizure frequency? 




What is the prevalence of vitamin D 
supplementation? 
Vitamin D supplement use Frequency 
What is the average number of times vitamin D 
supplementation was taken for past 30 days? 
Vitamin D supplement use Mean 
What is the average number of servings of 
vitamin D rich food consumed (for past 30 days)? 
Vitamin D rich diet Mean 
 
  




Appendix K – Vitamin D intake among older adults with epilepsy survey 
1. With full knowledge of all foregoing, I agree, of my own free will, to participate in this study. 
☐Yes, I consent 
☐No, I do not consent 
2. Do you have epilepsy/seizure disorder? 
☐Yes 
☐No 
3. Are you aged 50 years or older? 
☐Yes 
☐No 
4. Have you ever been diagnosed with any type of cognitive impairment? 
☐Yes 
☐No 
5. Please state your age in years. (Move bar to the right to select age) 
>Options: 0–150 
_______________ 
6. What is your ethnic background? Please mark all that apply: 
☐White 
☐Black (e.g., African, Caribbean, North American) 
☐First Nation/Aboriginal/ Métis/Inuit 
☐East Asian (e.g., Chinese, Korean, Japanese, Filipino) 
☐South Asian (e.g., East Indian, Pakistani, Sri Lankan) 
☐Latin American/Central American/South American (e.g., Mexican, Brazilian, Chilean, 
Guatemalan) 
Other (please specify): [text box] _____________ 
7. What is your biological sex? 
☐Male 
☐Female 
8. Are you post-menopausal? 
☐Yes 
☐No 
The next questions are about your personal experience with seizures/epilepsy: 
9. At what age did you experience your first seizure? (Move bar to the right to select age) 
>Options: 0–100 
______________ 




11. Which of the following seizure medications are you currently taking or have taken in the past? 
For how long? Please leave duration unanswered for medications that you have never taken. 
☐ Acetazolamide (Acetazolam)  
How long (in years or months)?______________________________________________ 
Currently taking? ☐Yes ☐No 
☐ Carbamazepine (Tegretol, Mazepine) 
How long (in years or months)?______________________________________________ 
Currently taking? ☐Yes ☐No 




☐ Clobazam (Frisium)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Clonazepam (Rivotril, Clonpam) 
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Diazepam (Valium, Diastat, Diazemuls, Dipam)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Ethosuximide (Zarontin)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Fosphenytoin (Cerebyx) 
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Gabapentin (Neurontin)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Lacosamide (Vimpat)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Lamotrigine (Lamictal)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Levetiracetam (Keppra)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Lorazepam (Ativan, Loraz)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Nitrazepam (Mogadon, Nitrazedon)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Oxcarbazepine (Trileptal)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Phenobarbital (Phenobarb)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Phenytoin (Dilatin, Tremytoin)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Pregabalin (Lyrica)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Primidone  




 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Rufinamide (Banzel)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Stiripentol (Diacomit)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Topiramate (Topamax)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Valproic Acid (Epival, Depakene, Depakote, Valproate)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
☐ Vigabatrin (Sabril)  
 How long (in years or months)?______________________________________________ 
 Currently taking? ☐Yes ☐No 
 Other, please specify medication name, number of years taken and if you are still currently taking 
it:  ____________________________________________________________________ 
 
We are interested in your typical eating habits: 
12. In the past 30 days, how often did you have a serving of food rich in vitamin D? For example a 
serving would be 1 cup of milk to drink or on cereal, 75g (2 ½ oz) of fish or pork, 2 egg yolks, 
or 1 teaspoon of margarine or cod liver oil. (Move bar to the right to select number) 
>Options: 0–100 
______________ 
The next questions are about any dietary supplements you take, both prescription and non-prescription: 
13. In the past 30 days, have you taken supplements?  
☐Yes 
☐No, I do not take supplements 
14. In the space provided beside each supplement, please indicate how many times in the past 30 
days you took the supplement (i.e. 0, 1, 2, 3 …100). Leave the space blank if you do not take 
that specific supplement. If you take a combination product, please also list the ingredients. If 
you take a Multivitamin, please also state the brand. 
Calcium: [text box] ____________ 
Vitamin D [text box] ___________ 
Combination product (e.g. Calcium + Vitamin D, Magnesium + Vitamin D), please list the 
ingredients: [text box] _____________ 
Multivitamin, please state the brand: [text box] ______________ 
15. In the space provided beside each supplement, please indicate what is the dose per one (1) 
pill/tablet/serving (for example, 200 mg, 800 IU, etc.). Leave the space blank if you do not take 
that specific supplement. 
Calcium [text box] ___________ 
Vitamin D [text box] __________ 
Combination product (e.g. Calcium + Vitamin D, Magnesium + Vitamin D): [text box]______ 
Multivitamin [text box]______________ 
16. For what reason do you take these supplements? (Please mark all that apply) 
☐ For my general health 




☐ Specifically for my bones/bone health 
☐ For my seizures/epilepsy 
☐ It was recommended by my doctor 
☐ Other (please specify): [text box] ____________________ 
Next, we will ask you some questions about your bone heath: 
17. Has your doctor told you that you have osteopenia/osteoporosis? 
☐Yes 
☐No 
18. Are you aware that some medications used to treat seizures are thought to affect bones (for 
example linked to osteoporosis and fractures)? 
☐Yes 
☐No 




☐My own research 
☐Family/Friends 
Other (please specify): [text box] ________________________________ 
 
Questions 1–4 are available only online and answers are mandatory to move forward 
  




Appendix L – Recruitment protocol 
 
 
Send link with attached information 
letter, link to online survey (Survey 
Monkey) and statement that they may 
request a mailed survey instead. 
Participants will be assigned ID numbers 
on online survey. Information letter and 
feedback letter will be included at start 
and end of online survey package 
respectively. Consent given by opening 
link and completing survey. 
Meets eligibility criteria 
Contact epilepsy support groups, clinics, independent living facilities Open recruitment via flyers 
Contact information of individuals who have 
participated in previous studies and have indicated 
interest in participating in future studies. 
Upon receiving contact from interested 
individuals via email address or phone 
number included in advertisement. 





Mail survey with 
information letter, 
written consent and 
feedback letter in 
package. Participants 
will be assigned ID 
numbers (separate from 
online surveys). 
Does not meet eligibility criteria, then exclude 
Reminder to complete survey (email or phone call) every two weeks for a total of three times 
